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ABSTRACT
The endoplasmic reticulum (ER) is the site of co- and post-translational
modification for secretory proteins. In order to prevent vesicular transport and secretion
of misfolded or misassembled proteins, a highly regulated mechanism called ERassociated degradation (ERAD) is employed. This pathway recognizes misfolded
proteins in the ER lumen and targets them to the cytosol for ubiquitination and
subsequent degradation via the 26S proteasome. Sec61 and Derlin-1 are ER pores
through which export occurs. AB-type protein toxins such as cholera toxin (CT), Shiga
toxin (ST), exotoxin A (ETA), and ricin have evolved means of exploiting the ERAD
pathway in order to reach their cytosolic targets. AB-type protein toxins consist of a
catalytic A-subunit and a cell-binding B-subunit. The B-subunit recognizes cell surface
receptors for the toxin. This begins a series of vesicle trafficking events, collectively
termed retrograde trafficking, that lead to the ER. Dissociation of the A and B subunits
occurs in the ER, and only the A subunit enters the cytosol. The exact mechanism of A
subunit translocation from the ER to the cytosol is unknown.
Toxin translocation occurs through a pore in the ER membrane. Exit through the
pore requires the toxin to be in an unfolded conformation. The current model for toxin
translocation proposes that ER chaperones actively unfold the toxin A chain for
translocation. After the translocation event, the toxin spontaneously refolds to an active
conformation. Our model suggests that unfolding in the ER is spontaneous and
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refolding in the cytosol is dependent upon cytosolic chaperones. Based on our model,
we hypothesize that blockage of the A subunit unfolding and/or the ERAD translocation
step will confer a phenotype of non-harmful multi-toxin resistance to cells. In support of
this model, we have shown that, at 37ºC, the isolated catalytic subunit of cholera toxin
(CTA1) is in an unfolded and protease sensitive confirmation that identifies the toxin as
misfolded by the ERAD pathway. Stabilization of CTA1 via glycerol inhibits the loss of
its tertiary structure. This stabilization results in decreased translocation from the ER to
the cytosol and increased secretion of CTA1 to the extracellular medium. Treatment
with glycerol also prevents CTA1 degradation by the 20S proteasome in vitro. These
data indicate that the thermal stability of CTA1 plays an important role in intoxication.
These data also suggest that stabilization of CTA1 tertiary structure is a potential target
for therapeutic agents.
Our model asserts that CTA1 behaves as a normal ERAD substrate upon
dissociation from the holotoxin. In support of this model, we have shown that the ER
luminal protein HEDJ, known to be involved in ERAD, interacts with CTA1. The
interactions between HEDJ and CTA1 occur only at temperatures in which the toxin is in
an unfolded conformation. We have also shown that HEDJ does not affect the
thermally stability of CTA1 since there is no alteration in its pattern of temperaturedependent protease sensitivity. Alteration of the normal HEDJ-CTA1 interaction via a
dominant-negative HEDJ construct resulted in decreased translocation from the ER to
the cytosol and, as a result, decreased intoxication.
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Our work demonstrated toxin resistance can result through effects on toxin
structure or ERAD chaperones. To identify other potential inhibitors, we developed a
novel assay to detect the activity of other AB toxins and compared it with an established
toxicity assay. We generated a Vero cell line that expressed a destabilized variant of
enhanced green fluorescent protein (EGFP). These cells were used to monitor the Stxinduced inhibition of protein synthesis by monitoring the loss of EGFP fluorescence from
cells. We screened a panel of 13 plant compounds, and indentified grape seed extract
and grape pomace extract as inhibitors of Stx activity. Grape seed extract and grape
pomace extract were also shown to block the toxic activities of ETA and ricin, providing
the basis for a future high-throughput screen for multi-toxin inhibitors.
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CHAPTER 1 INTRODUCTION
1.1 Intracellular Trafficking
Cells utilize several different endocytic mechanisms. The best
characterized of these mechanisms involves clathrin coated pits and vesicles1,2.
Clathrin dependent endocytosis, also referred to as receptor-mediated
endocytosis, serves to procure nutrients from the extracellular environment. This
type of endocytosis occurs on special coated pits localized on the plasma
membrane. Ligand from the extracellular environment binds to specific cellsurface receptors that trigger a signaling cascade to recruit clathrin to the
cytosolic face of the plasma membrane. Clathrin forms a three-legged structure.
When clathrin is recruited to the plasma membrane it binds to other clathrin
molecules creating a mesh underlying the ligand receptor complex and causing
the plasma membrane to invaginate and pinch off. In addition to clathrindependent endocytosis, internalization can proceed via either caveolaedependent endocytosis or much less studied mechanisms that do not utilize
either clathrin or caveolae. Caveolae-dependent endocytosis is characterized by
the involvment of the 22-kD membrane-associated protein, caveolin. Caveolae
are invaginated plasma membrane domains enriched in cholesetrol and
glycosphingolipids3-7. Caveolin binds cholesterol and aids in forming and
stabilizing the invaginated membrane domains.
The secretory pathway is the export pathway for the cell. Proteins that are
synthesized in the endoplasmic reticulum (ER) are packaged for transport to the
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extracellular surface in an anterograde fashion. A secondary transport pathway
to maintain membrane homeostasis must offset the secretory pathway. This
retrograde pathway is used to recycle proteins and lipids involved in the
secretory pathway and takes places in three different steps: 1) transport from
endosomes, early (EE) or late (LE), to the trans-Golgi network (TGN); 2) intraGolgi transport; 3) transport from the Golgi to the ER.
Transport from the endosomes to TGN has been shown to occur by two
routes. The first endosome to TGN traffic route is the Rab9-dependent
pathway8,9. Characterized by the involvement of the small GTPase Rab9, this
pathway recycles the mannose-6-phospahte receptor to the TGN after M6PR
transports newly synthesized lysosomal enzymes to the LE. Rab9 organizes the
membrane for tranport to the TGN. The second endosome to TGN transport
pathway is thought to function between the recycling endosomes, a subclass of
the EE, via another small GTPase, Rab11 that regulates membrane distribution
inside the recycling endosomes10.
The intra-Golgi transport pathway is a difficult problem to solve.
Anterograde transport within the Golgi complex has yet to be clearly elucidated.
It is possible that transport occurs via vesicular carriers11. Another argument is
that transport occurs via the maturation of Golgi cisternae12. Both sides of the
argument are in agreement however, that vesicle-mediated retrograde transport
within Golgi must occur to maintain Golgi homestasis. Identification of the
machinery involved with intra-Golgi retrograde transport is difficult to confirm due
to the lack of methods to monitor traffic biochemically.
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Retrograde traffic from the Golgi to the ER also utilizes multiple pathways.
The first pathway involves the binding of a KDEL retrieval sequence to KDEL
receptors in the Golgi (COPI-dependent)13-15. Binding of KDEL-tagged proteins
to the KDEL receptor allows for the binding of the small GTPase Arf1. Arf1 in its
activated form (Arf1-GTP) is recruited to the cargo/cargo receptor complex. Arf1
then recruits COPI coat protein complex which promotes vesicle formation.
COPI coated vesicles are targeted to the ER where vesicular SNAREs (vSNARE) bind to target SNARES (t-SNARES) on the ER and promote ER-vesicle
fusion. A number of protein toxins have been shown to contain a KDEL
sequence and thus utilize the COPI-dependent pathway16-18. There are,
however, a subset of these protein toxins that are still able to traffic to the ER
when COPI trafficking is blocked by either compounds or mutant cell lines
suggesting an alternate, COPI-independent pathway. Little is known about this
COPI-independent pathway except that vesicular rafficking is dependent on the
small GTPase Rab619,20.
Export from the ER to the cytosol occurs through one of two pores located
on the ER membrane: Sec6121-27and/or Derlin-128. The Sec61 protein complex is
the major apparatus utilized during co-translational translocation of proteins
destined for secretion or organelles in the endomembrane system. Ribosomes
bind the mRNA and translation of the proteins begins. Translation results in an
N-terminal signal sequence. A signal recognition protein (SRP) binds to the
ribosome and the translated signal sequence halting translation of the protein.
The ribosome-SRP complex binds to an SRP receptor located on the ER
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membrane, which transfers the ribosome to the Sec61 translocon. Transfer to
the Sec61 translocon allows release of the SRP and SRP receptor and protein
translation resumes into the ER lumen. Immediately upon entering the ER the
newly synthesized protein undergoes a number of post-translational
modifications. The signal sequence is cleaved and glycosylation occurs to help
promote proper folding and assembly. If the proteins are unable to fold properly
they are exported back through the Sec61 translocon through a process called
ER associated degradation29. Recent evidence has revealed that a second pore
is capable of retro-translocation. Overexpression of a dominant-negative Derlin1 inhibited the ER to cytosol transfer of the catalytic subunit of cholera toxin
(CTA1), suggesting Derlin-1 is responsible for CTA1 retro-translocation28.

1.2 ER Associated Degradation
The ER is the site for folding and maturation of proteins destined for
secretion or residence within other organelles of the endomembrane system. As
proteins are co-translationaly translocated across the ER membrane several
covalent modifications take place. These modifications are a part of the quality
control system within the ER to ensure proper folding and organelle distribution.
The ER also contains numerous molecular chaperones that serve to correct nonnative conformations. BiP is a member of the Hsp70 family that recognizes
misfolded proteins by binding to hydrophobic amino acid sequences that are
normally buried in properly folded proteins30. ER DNA J homologue proteins
(ERdj) serve to stimulate the function of BiP31. Protein disulfide isomerase (PDI)
helps to form disulfide bonds by catalyzing the oxidation and isomerization of
4

sulfhydryl groups on cysteines32. Calnexin and calreticulin are lectins that bind to
monoglucosylated N-linked oligosaccharides that occur after removal of glucose
residues by ER glucosidases. ERp57 interacts with the calnexin- or calreticulinbound proteins to generate disulfide bonds33,34. Glucosidase II removes the final
glucose from the protein. If the protein is correctly folded, glucosyltransferases
(GT) will not be able to add glucose sugars to the protein and it can be exported
from the ER. In the event that the protein is incompletely folded, the GT will add
a glucose residue and return the protein to the calnexin/calreticulin cycle in an
effort to fold the protein properly35. In the event that the protein cannot attain a
native conformation, the proteins are selected for retro-translocation to the
cytoplasm where they can be degraded by the 26S proteasome. Terminally
misfolded proteins are targeted to the Sec61 and/or Derlin-1 pores by a complex
of BiP and at least one HSP40 co-chaperone, HEDj or ERdj336. Upon export
from the ER lumen, the misfolded proteins are ubiquitinated. The 19S cap of the
proteasome recognizes the ubiquitinated proteins and further unfolds the proteins
for degradation by the 20S proteasomal core37.

1.3 AB Type Protein Toxins
Plants and bacteria utilize a number of protein toxins for cytotoxic or
cytopathic activity in mammalian cells. One group of these protein toxins is
referred to as AB-type protein toxins. This group of toxins includes: cholera toxin,
ricin, Shiga toxin, exotoxin A, pertussis toxin, diphtheria toxin and anthrax toxin.
These toxins are characterized by their catalytic A subunit and their cell binding B
subunit. AB-type protein toxins bind to a wide assortment of cell receptors and
5

utilize multiple endocytic pathways.38-40 These toxins attack a wide array of
cytosolic targets with various enzymatic activities (Table 1). The one thing all
these toxins have in common is that they all bind to the extracellular surface of
mammalian cells and must find a way to translocate across a membrane to reach
their cytosolic targets. AB protein toxins bind to the cell surface and are
internalized by varying endocytic mechanisms. Diphtheria toxin and the anthrax
toxins are able to escape the endosomal compartment by virtue of pH-induced
conformational rearrangement that allows these toxins to create their own pore
within the endosomal membrane41,42. The other AB toxins listed above are
trafficked to the ER42-45. Upon arrival in the ER, the A subunit dissociates, attains
a conformation that mimics a misfolded protein, and is targeted by ERAD for
retro-translocation out of the ER. As previously mentioned, ERAD substrates are
ubiquitinated and targeted to the proteasome for degradation46. Ubiquitination
occurs on lysine residues of ERAD substrates. AB toxins are capable of avoiding
proteasomal degradation due to their lysine deficiency in the A subunits47. Now
released from the ER membrane system and unaffected by proteasomal
degradation, the toxins are free to attack their cytosolic targets.
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Table 1-1 AB Protein Toxins
Organism

Structure

Cell Surface
Receptor

Endocytic
Mechanism

Endosome→Golgi

Golgi→ER

Intracellular
Target

Activity

Corynebacterium
diphtheriae

AB

HB-EGF

Clathrin- and Caveolae
Independent

NA

NA

EF-2

ADP-Ribosyl
transferase

Anthrax
41
(Lethal)

Bacillus anthracis

A2B7

TEM8/CMG 2

Clathrin Dependent

NA

NA

MAPKK

Zinc
Endoprotease

Anthrax
41
(Edema)

Bacillus anthracis

A2B7

TEM8/CMG 2

Clathrin Dependent

NA

NA

cAMP Induced
Protein Changes

Adenylate
Cyclase

Shigella
dysenteriae

AB5

Gb3

Clathrin Dependent

Rab11

COPI
Independent

28S rRNA

N-glycosidase

Escherichia coli
(STEC)

AB5

Gb3

Clathrin Dependent

Rab11

COPI
Independent

28S rRNA

N-glycosidase

Bordetella
Pertussis

AB5

Unknown

Clathrin Dependent

Rab9

COPI

Heterotrimeric GProtein

ADP-Ribosyl
transferase

Vibrio cholerae

AB5

GM1

Caveolae Dependent

Rab9

COPI

Heterotrimeric GProtein

ADP-Ribosyl
transferase

Psudeomonas
aeroginosa

AB

Low-Density LRP

Clathrin Dependent

Rab9

COPI

EF-2

ADP-Ribosyl
transferase

Ricinus
communis

AB

Terminal Galactose
Residues

Clathrin Dependent
and Independent

Rab11

COPI
Independent

28S rRNA

N-glycosidase

Toxin
42,45

Diphtheria

Shiga

43,48

43,48

Shiga-Like
Pertussis
Cholera

42,45

42,44,45

Exotoxin A

42,45

45,48

Ricin

Table compiled from references41-45
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1.4 Models for Translocation
As previously stated, the problem shared by all AB toxins is the necessity
for traversing the organelle membrane barrier for intoxication. DT and anthrax
toxin are able to escape the endosomal membrane system by virtue of pHinduced alterations in protein structure that allow the toxins to create their own
pore to the cytosol. The other listed toxins are incapable of self-translocation and
must rely on pores already in existence within the cell. The toxins travel in a
retrograde fashion to the ER where they can mimic misfolded proteins to co-opt
the ERAD system for export to the cytosol49,50. CT escape from the ER requires:
reduction of the disulfide bond between the A1 and A2 subunits, disassembly of
the holotoxin into CTA1 and CTA2-CTB, and unfolding of the A1 subunit into a
translocation competent state. Reduction the disulfide bond occurs when the
holotoxin arrives in the ER. Although the conditions of the ER are normally
suited for disulfide bond formation, the GSH/GSSG ratio within the ER is capable
of reducing the disulfide bond that bridges CTA1 and CTA2-CTB51. PDI then
facilitates the disassembly of the reduced holotoxin. It has been reported that
PDI also plays a role in the active unfolding of the CTA1 subunit52. The current
model for CT translocation suggests that the holotoxin is reduced in the ER, and
PDI unfolding of holotoxin-associated CTA1 is what dislodges CTA1 from the
holotoxin. An alternate model presented here suggests that CT is reduced in the
ER and that PDI mediates dissocation of the CT subunits. However, we believe
that PDI serves only to dislodge the CTA1 from the rest of the toxin and that it
does not actively unfold CTA1. In contrast to the current model, we show that
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CTA1 is a thermally unstable protein and that dissocation from the rest of the
holotoxin allows spontaneous unfolding of the CTA1 subunit into a translocation
competent conformation. PDI does not have to unfold CTA1; it only needs to
remove CTA1 from the A2/B portion of the toxin. We predict that stabilization of
the dissociated CTA1 subunit by interactions with chemical chaperones will
prevent the subunit from reaching a translocation competent conformation.
Stabilized CTA1 will be unable to exit the ER resulting, preventing intoxication.
We further predict that disruption of the interactions between CTA1 and ERAD
molecular chaperones will also prevent the subunit from exiting the ER. The
current model suggests that PDI actively unfolds CTA1 and delivers the toxin
directly to the Derlin-1 pore. We predict that unfolded CTA1 will behave as an
endogenous misfolded protein and interact with other ER molecular chaperones.

1.5 Cholera Pathogenesis
1.5.1 Brief History
Cholera is one of the oldest diseases known and has been endemic in
certain regions of the world since history was recorded. The origins of cholera
can be linked to the Indian subcontinent with the River Ganges serving as a
source of contamination. Over the last 200 years the disease has spread via
trade routes to Russia, Europe and the Americas over the course of numerous
pandemics. The first modern pandemic began in Bengal, India in 1816. By
1826, the end of the first pandemic, the disease had spread across India and
extended into China and Indonesia. The second pandemic starting in 1829 saw
the disease transition from a southern Asia issue to a worldwide concern. The
9

disease saw rapid spread from southern Asia to Russia and Germany by 1831,
England and France by 1832, Canada and the eastern coast of North America by
1834. By 1851, the disease had spread throughout the continental United
States. During the third cholera pandemic the epidemiological study conducted
by John Snow during the Soho Outbreak proved that contaminated water was
the source of the spreading disease. It wasn’t until the fifth pandemic between
1881 and 1896 that Vibrio cholerae was determined to be the causative agent.
Currently we are in the middle of the seventh cholera pandemic. This pandemic
originated in Indonesia and the causative agent was identified as a biotype V.
cholerae serogroup O1 called El Tor. In 1992, a new, non-O1 serogroup of V.
cholerae was identified and designated O139 Bengal53,54. At the time, only
serogroup O1 was known to cause epidemic outbreaks of cholera. It is believed
that the next pandemic of cholera will be attributed to O139 Bengal.

1.5.2 Epidemiology
Vibrio cholerae is a Gram-negative facultative anaerobe. Of the roughly
200 identified serogroups, only O1 and O139 are capable of producing the toxin
necessary for cholera disease. Cholera has long been referred to as the “classic
water-borne” disease, thanks in large part to the Soho outbreak in London,
although water is not the only source of the bacteria. V. cholerae can be
transmitted via contaminated food as well as contaminated water55. In fact, in
developed countries, contaminated shellfish is the typical cause of disease.
In countries where cholera has become endemic, outbreaks are
characteristically seasonal consisting of a major followed by a minor spike in
10

incidence every year 56. Vibrios grow more quickly at warmer temperatures,
which seems to be the cause of the seasonality. A relationship has also been
established between the presence of pathogenic V. cholerae and cholera lytic
phages in the aqueous environments56. Epidemic outbreaks of cholera coincided
with the presence of pathogenic V. cholerae in water samples. The time
between the outbreaks is characterized by an absence of pathogenic V. cholerae
but the presence of high numbers of cholera phages.
During cholera epidemics, the highest attack rates are in children between
the ages of 2 and 4 years57. In areas where the disease is new, the attack rate is
similar among all age groups. The disease requires a high infectious dose of
bacteria (108 bacteria) to cause severe symptoms in healthy adults, however a
much smaller dose (105 bacteria) can cause disease under conditions where the
stomach acids have been neutralized.

1.5.3 Disease/Treatment/Prevention
Cholera is the most severe diarrheal disease. Fluid losses up to 30 liters
per day have been reported58. The onset of symptoms are generally rapid and
without warning after an incubation period between 18 hours and 5 days. The
most characteristic symptom of disease is the high volumes of rice-water stool
that that is purged. Vomiting is also likely to occur. Due to the high volume of
fluid loss, the main concern with disease onset is dehydration resulting in
hypotonic shock. Treatment for the disease is very simple; replace the
electrolytes as fast as they are being lost. If fluids are administered promptly via
oral rehydration or intravenous drip, nearly all deaths are avoidable. Without
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treatment however, fatality rates can reach as high as 50%59. Since
contaminated food and water sources are the primary modes of transmission,
methods to maintain safe food and water supplies are effective means of
decreasing disease prevalence. Improving sanitation, thoroughly cooking highrisk foods, and education on public health are all effective means of prevention.
Vaccinations for the disease have been administered since the 1880’s. The first
cholera vaccine was a killed, whole-cell, injectable vaccine. The original vaccine
provided only a brief protection (6 months) and was ultimately determined not to
be cost-effective. New oral vaccines, Dukoral, Orochol, and Choleragarde are
being administered over seas and promise substantial protection without side
effects.

1.5.4 Virulence Factors
V. cholerae pathogenesis is reliant upon two primary virulence factors.
The first is the toxin-coregulated pilus (TCP) encoded on the region of the vibrio
genome referred to as the vibrio pathogenicity island (VPI). Ingestion of
contaminated food or water sources leads to colonization of the upper small
intestine. Bacterial colonization is aided by filamentous protein structures called
TCP60. The TCP extends out from the cell and attaches to an unidentified
mucosal receptor(s)61. The second virulence factor and primary cause for
disease is cholera toxin (CT). Genes encoding the toxin are located on the CTX
genetic element, which is actually the genome of a lysogenic bacteriophage
CTXφ. The CTXφ utilizes the TCP as a receptor during infection of the
bacteria62,63. CT is an AB toxin with a single catalytic A subunit and a cell binding
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homopentameric B subunit64. CTA is synthesized as a single polypeptide chain
and is post-translationally cleaved into A1 and A2 fragments linked by a disulfide
bridge58. The CTA2 fragment inserts into the central pore of the doughnutshaped CTB pentamer, and remains linked through noncovalent interactions.
The type II secretion system mediates release of CT. The B subunit of the toxin
binds to GM1 cell surface receptors where it can be endocytosed. The holotoxin
then proceeds in a retrograde fashion through a series of vesicular trafficking
events to the ER44,65-67. In the ER, the A subunit dissociates from the B subunit
and is translocated into the cytosol via ERAD. In the cytosol, CTA1 catalyzes the
ADP ribosylation of Gsα68, one-third of the heterotrimeric G protein. ADPribosylation of Gsα causes the protein to remain in its active GTP-bound state,
which then leads to constituitive activation of adenylate cyclase, resulting in
increased intracellular cAMP concentrations68. The increased levels of cAMP
stimulate chloride secretion from the cells and prevents sodium uptake resulting
in osmotic differences between the intracellular and extracellular space64. To
balance out the osmotic differences, water is secreted from the cell and the
overall result is a voluminous loss of water from intestinal epithelial cells.

1.5.5 Ecology
It is generally believed that cholera was spread from infected people to
others via fecal contamination of water and food supplies. Any global
movements of the disease were a result of global movements of populations.
Studies, however, have shown that Vibrio cholerae are normally found in surface
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water and can multiply independently of humans69,70. When outside of human
hosts, the bacteria can be found as free-swimming cells, or attached to surfaces
as biofilms where they are in a viable but non-culturable state due to depravation
of essential nutrients71. This independence of human hosts and the ability to
survive in surface waters has led many to believe that global spread of the
disease is more likely due to ship ballast than global population movements72.

1.6 Shiga Toxin Pathogenesis
1.6.1 Brief History
Shiga toxin is a protein toxin produced by Shigella dyseneteriae and the
Shigatoxigenic group of E. coli (STEC), most notably E. coli O157:H7
(EcO157)73. The toxins are named after Kiyoshi Shiga, who first attributed the
origin of the disease dystentery to the bacterium Shigella dysenteriae in 1903. It
was not until 1977 that Shiga toxin (ST) production was found in E. coli, although
it was referred to at the time as verotoxin for the ability to intoxicate Vero cells74.
Both bacteria are enteric pathogens capable of causing varying degrees of
gastrointestinal illness, watery diarrhea being the mildest and hemorrhagic colitis
(bloody diarrhea) the most serious75. Severe cases can lead to hemolytic uremic
syndrome (HUS). HUS is a disease brought on by damage done to kidney cells
by Stx causing acute renal failure75. It is hypothesized that EcO157 evolved from
the enteropathgoneic E. coli (EPEC) O55:H7.
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1.6.2 Epidemiology
EcO157 was first indentified as a pathogen during an investigation of a
hemorrhagic colitis outbreak in 1982. It wasn’t until 1993; with a multistate
outbreak initiated by undercooked ground beef from a fast-food chain that
EcO157 began to receive recognition as a major threat to public health. It has
been estimated that EcO157 causes approximately 73,000 cases of illness,
2,000 hospitalizations, and 61 deaths per year76. The majority of EcO157 cases
are attributed to either food- or water-borne sources. Ground beef has been the
major source of food-borne disease for some time; however, increased
consumption of produce has led to an increased number of produce-related
outbreaks77. Ground beef related illness has been linked to the consumption of
undercooked meat harboring EcO157. Contamination of produce can be linked
to a number of factors. Treatment with poorly composted manure, exposure to
contaminated water, or fecal contamination have all been linked to EcO157
produce contamination78-80.

1.6.3 Disease/Treatment/Prevention
Shiga intoxication ranges from mild, uncomplicated diarrhea to
hemorrhagic colitis. The infectious dose for EcO157 is small. In the 1993
outbreak it was determined that each hamburger patty only contained 700
bacteria and some individuals only ate a few bites81. In a 1994 outbreak
involving salami, the infectious dose was found to be only 50 organisms81.
Disease symptoms typically appear 3-4 days post-ingestion. Initial symptoms
are represented by non-bloody diarrhea and abdominal cramps. 2-3 days
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following initial signs of disease, the symptoms progress to bloody diarrhea82.
Typically symptoms only remain for a week and then the disease resolves.
Occasionally infected individuals develop symptoms that progress to HUS. It is
thought that ST can bind to a number of different components in the circulatory
system (blood group antigens, B lymphocytes, platelets, monocytes and
lipoproteins) and that this is how the toxin is transported throughout the body,
most notably to the kidneys. High concentrations of Gb3 are found in renal
tubular cells and microvascualar endothelial cells in the glomerulus of the
kidney83. Intoxication of these cells results in cell death. Platelets bind to the
damaged endothelium and begin to aggregate. The platelet aggregation
ultimately blocks the glomerulus and prevents the filtration of the blood resulting
in acute renal failure.

1.6.4 Virulence Factors
STEC strains belong to a wide array of serotypes that are capable of
causing disease in humans. While several E. coli strains such as E. coli 0111:H8
and E. coli 026:H11 are capable of producing Stx, EcO157 is the most prolific of
the STEC strains and most commonly associated with large outbreaks84. ST is
produced by STEC and secreted to the periplasmic space of the bacterium. The
toxin is an AB5 toxin that requires activation via furin cleavage of the A and B
subunits85. Although a small amount of Shiga toxin is capable of escaping the
bacterial periplasm and entering the host extracellular space, the majority of toxin
release requires lysis of the bacterial cell. STEC cell lysis occurs when host
immune responses attempt to remove the invading bacteria. Free toxin is then
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able to bind to the cell surface glycolipid globotriaosylceramide (Gb3)86.
Internalization of the toxin proceeds via clathrin-dependent endocytosis87,88.
Furin cleavage occurs in the host cells and has been localized to the trans-Golgi
network and the endosomes48. The toxin is trafficked to the ER in a retrograde
manner via Rab11- and COPI-dependent vesicular transport from the
endosomes to the Golgi apparatus and the Golgi apparatus to the ER
respectively48. In the ER, Stx, like CT, mimics a misfolded protein and is
transported into the cytosol by ERAD for degradation by the proteaseome.
Through a dearth of lysine residues, Stx is capable of avoiding ubiquitindependent degradation by the 26S proteasome. In the cytosol Stx is free to act
on its cytosolic target, the 28S rRNA. Stx cleaves the N-glycosidic bond of A4324
in the 28S rRNA of the 60S ribosomal subunit resulting in inhibited protein
synthesis and eventually cell death89.
There are two different Stxs that are produced by the STEC strains, Shiga
toxin-1 (ST-1) and Shiga toxin -2 (ST-2)89. Both subgroups of the toxin are
phage encoded in E. coli. The toxins have indistinguishable in vitro enzymatic
activity, however, their toxicity varies greatly. In mice, the lethal dose (LD50) was
shown to be approximately 400 ng for ST-1 and only 1 ng for ST-290. The
difference in toxicity is also seen in human endothelial cells with ST-2 being
1,000 fold more toxic than ST-191. Molecular details for differences in toxicity
have yet to be elucidated.
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CHAPTER 2 MATERIALS AND METHODS
2.1 Tissue Culture
Cells seeded to a 10 cm dish were washed once with PBS. 1 ml of
trypsin-EDTA was added to the plate and incubated at 37°C for 5 minutes. 9 mls
of the appropriate complete tissue culture media (containing 10% fetal bovine
serum and 1% antibiotic-antimycotic) was added to the plate and titurated to
resuspend the cells. CHO cells require Ham’s F-12; HeLa, Vero and Verod2eGFP require DMEM. 9 mls of complete media was added to a new 10 cm
dish and 1 ml of the cell resuspension was added to the new 10 cm dish. The
seeded dish was rocked back and forth to ensure even distribution of the cells on
the plate. When the cells reached 80% confluency on the 10 cm dish, they were
again split.
Variations of the above protocol were used for alternate incubation times
and for seeding to alternate plates. The dilution of 1 ml cell resuspension to 9 ml
complete media reached 80% confluency after 3-4 days of incubation at 37°C. A
dilution containing 0.5 ml of cellular resuspension and 9.5 ml of media was often
used to extend the incubation of cells to 4-5 days. For incubation times greater
than three days, the media was removed and replaced with 10 ml of fresh media.
Cells that were seeded into a 6-well plate required a dilution of 1 ml cellular
resuspension to be added to the well along with an additional 0.5 ml of media.
Cells seeded into 6-well plates at this dilution reached 80% confluency in 18-24
hours. Cells that were seeded to 24-well plates required a dilution of 1 ml of
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cellular resuspension to be mixed with 5 ml of complete media. 0.5 ml of the 1:6
dilution was added to each well of a 24-well plate for use after an overnight
incubation.

2.2 Transfection
CHO cells were seeded to a 6-well plate and grown to 80% confluency
following an overnight incubation at 37°C. Following the incubation transfection
mixtures were prepared in eppendorf tubes. Solution A was placed in one tube
consisting of 1 µg of DNA per 100 µl of serum free media. Solution B was placed
in a separate tube consisting of 5 µl of lipofectamine reagent per 100 µl of serum
free media. Solution A and solution B were then combined and incubated at
room temperature for 30 minutes. The cells were washed with 2 ml of serumfree media to remove any residual media the cells were seeded in. One ml of
serum-free media was added to each well followed by 200 µl of the
DNA/lipofectamine transfection mixture. Following a 3 hour incubation at 37°C,
the transfection mixture was removed, the cells were washed with antibiotic- and
serum-free media and 1.5 ml of serum-free media was added for overnight
incubation at 37°C. Co-transfection assays in CHO cells consisted of 1 µg of
DNA for each plasmid per 100 µl of serum-free media. Solution B remained the
same.
For transfection of HeLa cells solution A consisted of 0.5 µg of DNA per 100
µl of serum-free media, and solution B consisted of 8 µl of lipofectamine per 100
µl of serum-free media. HeLa cells were incubated with transfection mixture for 5
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hours at 37°C. All other steps were identical to the above protocal for
transfection of CHO cells.

2.3 GST-HEDJ Protein Purification
A starter culture of E. coli containing the pGEX-HED2 expression
plasmid31 was grown overnight at 37°C in 50 ml of LB broth. After the overnight
incubation the starter culture was added to 1 L of LB broth and grown at 37°C to
an A600 of ~0.6 in an orbital shaker incubater at which point IPTG was added to a
final concentration of 1 mM. Following another 2 hour incubation the cells were
pelleted for 10 minutes at 10,000 g and frozen for at least 30 minutes at -20°C.
The pellet was then re-suspended in 10 ml of 1% Triton X-100 in PBS and lysed
by sonicating for 20 seconds on ice and then incubation for 40 seconds on ice.
The sonication was repeated 4 times. The lysate was spun at 14,000 g for 15
minutes. The supernatant was applied to a 1 ml glutathione agarose column
attached to an Akta purifier. The column was washed with 5 ml of GST protein
purification binding buffer. GST-HEDJ was eluted off the column with binding
buffer containing 20 mM reduced glutathione and identified by Western blot.

2.4 Toxicity Assay – cAMP
Cells were seeded into flat-bottom 24 well plates and grown overnight to
80% confluency (in triplicate). The media was removed and replaced with
serum-free media containing the stated concentrations of CT in the absence or
presence of 10% glycerol. After a 2 hour incubation the cells were washed with
PBS and 0.25 ml of ice cold HCl:EtOH (1:100) was added for 15 minutes at 4°C.
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The liquid was removed, placed in microcentrifuge tubes and allowed to air dry.
cAMP levels were then determined using an [125I] cAMP competition assay kit as
per the manufacturer’s instructions. The values obtained were then background
subtracted from cells that were treated with no toxin. The maximum response
was arbitrarily set to 100% and all other values were expressed as a ratio of that
value.
For the toxicity assay with HEDJ transfected cell the above protocol was
modified. Cells were transfected with HED2, HED3 or pcDNA3.1 vector alone.
Following overnight incubation the cells were lifted from the 6-well plate with 0.5
ml of trypsin-EDTA and 1.5 ml of DMEM containing antibiotic-antimycotic and
10% fetal bovine serum (DMEM-FBS). The resuspension was diluted in 11 mls
of DMEM-FBS and seeded at 0.5 ml per well into 24-well plates and grown
overnight to 80% confluency (in triplicate). The remainder of protocol was
followed as described above.

2.5 Toxicity Assay – Protein Synthesis
Cells were seeded into flat-bottom 24-well plates and grown overnight to a
confluency of approximately 80% (in triplicate). The media was removed and
replaced with serum-free media containing various concentrations of toxin in the
presence or absence of 10% glycerol. After an incubation of four hours the cells
were washed with PBS, and methionine-free media was added for 30 minutes at
37°C. The media was removed and replaced with 0.25 ml methionine-free media
containing 10 uCi [35S] methionine/ml for 15 minutes at 37°C. Cells were washed
with 0.5 ml of 10% trichloroacetic acid in PBS for 30 minutes at 4°C, followed by
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a second wash for 15 minutes. The wash solution was removed and replaced
with 0.5 ml of 0.2N NaOH. The NaOH was removed from each well and loaded
into individual scintillation vials containing scintillation fluid for quantification on a
Beckman Coulter LS 6500 multi purpose scintillation counter. Data is expressed
as a percentage of the maximal signal for unintoxicated control cells.

2.6 Translocation/Secretion Assay
HeLa cells were seeded to 6-well plates in complete DMEM media to
achieve 10,000 cells/well after an overnight incubation at 37°C. Triplicate wells
were required for each condition. Following the overnight incubation the media
was replaced with serum-free, antibiotic-anticmycotic free DMEM (DMEM Only)
media containing 100 ng/ml of GM1 and incubated at 37°C. After a 1 hour
incubation, the media was replaced with 1 ml of DMEM only containing 1 µg/ml of
cholera holotoxin and placed at 4°C. After a 30 minute, incubation the media
was removed and the cells were washed prior to being lifted from the 6-well plate
using 750 µl of 0.5 mM EDTA in PBS per well. Both wells for each condition
were added to a single microcentrifuge tube and spun at 5,000 x g for 5 minutes.
The supernatant was discarded and the pellet was resuspended in 0.04%
Digitonin in HCN buffer and placed on ice for 10 minutes. The samples were
spun at 16,000 x g for 10 minutes and the supernatant was collected and placed
in a fresh microcentrifuge tube. Samples to be analyzed by Western blot
analysis received 120 µl of 1x sample buffer to the pellet fraction and 20 µl of 4x
sample buffer to the supernatant fraction. The samples were run on 15% SDSPAGE gels for electrophoresis. Samples to be analyzed by surface plasmon
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resonance (SPR) received HCN buffer to 1 ml. Samples for the co-transfection
translocation assays were resuspended to a volume of 1 ml in lysis buffer after
the final centrifugation step. These samples were pre-cleared with protein A
beads. Following an overnight incubation at 4°C, the samples were spun at
5,000 x g for 5 minutes. The supernatants were removed and placed into new
centrifuge tubes for immunoprecipitation.

2.7 Protease Sensitivity Assay
A master mix was created using 6 μg of CTA1/A2, 10 mM ßmercaptothanol and 20 mM sodium phosphate buffer pH 7.0 in a final volume of
120 ul. Where indicated, 10% glycerol was also present in the buffer. An aliquot
of 20 μl of the master mix was placed into 5 tubes and incubated at the indicated
temperatures for 1 hour. 8 µl of 4x sample buffer was added to the final 20 µl of
the initial master mix (input sample) and set aside. The incubated tubes were
place on ice at 4°C for 10 minutes. 2 µl of 0.4 mg/ml thermolysin was added to
all samples. Thermolysin samples were incubated on ice at 4°C for 1 hour. 2 µl
of EDTA was added to all incubated samples along with 8 µl of 4x sample buffer.
Samples were analyzed by SDS-PAGE and Coomassie staining.

2.8 In Vivo CTA1 Degradation Assay
CHO cells were transfected with ssCTA1 or mCTA1 expression plasmids.
24 hours after transfection, media was removed replaced with 0.5 ml of
methionine-free media for one hour. The media was replaced with 0.5 ml
methionine-free media with 150 μCi [35S] methionine/ml. After an hour
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incubation the cells were washed with PBS. 1 ml of serum-free media containing
excess unlabeled methionine (0.5 mg /ml) was added back to the three chase
plates for further incubations of 0, 1, 2 and 3 hours. At the end of the chase
intervals, the cells were given 1 ml of lysis buffer. Following a 20 minute
incubation at 4°C the liquid was removed, placed in microcentrifuge tubes and
spun at 14,000 rpm for 5 minutes. The supernatant was placed into a fresh
microcentrifuge tube and placed on a rocker for overnight incubation with 3 μl of
anti-CTA antibody. The liquid was then incubated on a rocker overnight with 40
μl of protein A slurry. The samples were spun down and washed twice with
NDET and once with water. 40 µl of 1x sample buffer was added to the pellet.
The samples were run on an SDS-PAGE gel and dried to filter paper using a BioRad gel dryer. Gels were placed in a Phopho Imager cassette for 4 days and
analyzed using a Storm 840 Phospho-Imager and Image Quant software. Pulse
samples (0 hour chase) were set to 100% value. Chase samples were
expressed as a percentage of the pulse. Background was subtracted from all
samples prior to data calculations. Mock transfections were performed to
demonstrate the specificity of CTA immunoprecipitation.

2.9 Western Blot Analysis
Twenty five microliters of sample was loaded to a 15% SDS-PAGE gel.
The samples were allowed to run at 150 Volts for 90-120 minutes. Gels were
washed 2 times in water and then equilibrated in transfer buffer for 10 minutes
along with 2 pieces of filter paper. PVDF membrane was placed in MeOH for 10
seconds and then transfer buffer for 10 seconds for activation. One piece of filter
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paper was placed on the bottom platinum anode of the transfer apparatus
followed by the activated membrane then the equilibrated gel and the second
piece of filter paper. Air bubbles were rolled out prior to securing the top cathode
and safety cover. The transfer was conducted for 20 minutes at 15 Volts and
then 40 minutes at 20 Volts. The membrane was then incubated overnight at
4°C in 1% milk in TBS-T with primary antibody (rabbit α-HSP90 1:20,000; rabbit
α-PDI 1:5,000; rabbit α-CTA 1:20,000). After incubation the membrane was
washed in 1% milk in TBS-T for 5 minutes. The membrane was then incubated
at RT for 30 minutes with secondary antibody (rabbit α-HRP 1:20,000).
Following incubation the membrane was washed once in 1% milk for 5 minutes
and once in TBS-T for 5 minutes. ECL Plus Western blotting detection reagents
were used for detection following manufacturers suggested protocol.

2.10 20S Proteasome Assay
A master mix was created using 1 μg 20S proteasome, 5 μg substrate, 3
μl 100 μM ATP, 10 μl 100 μM β-ME, 50 μl of 2x assay buffer to a final volume of
100 μl. One aliquot of 20 μl was placed in a separate eppendorf tube with 7 μl of
4x sample buffer. The remaining mix was incubated at 37°C. At 4, 8, and 20
hours of incubation, another 20 μl was removed from the master mix and placed
in a new eppendorf tube as was done with the first time point. Samples were
analyzed by SDS-PAGE and Commassie staining.
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2.11 Immunoprecipitation
Cells were seeded to 6-well plates and transfected as previously
described in triplicate. Cells were transfected with an empty vector (pcDNA 3.1),
mCTA1 plasmid or ssCTA1 plasmid. Following an overnight post-transfection
incubation, the cells were incubated for 1 hour at 37°C in 0.5 ml of methioninefree media. The cells were then washed with PBS and incubated for 1 hour at
37°C in 0.5 ml of methionine-free media containing 75 μCi [35S] methionine. The
cells were washed with PBS and lifted from the wells with 750 μl of 0.5 mM
EDTA in PBS and placed into separate microcentrifuge tubes. The tubes were
centrifuged at 5,000 x g for 5 minutes. The supernatant was discarded and the
cell pellet was resuspended in 100 μl of 0.04% digitonin in HCN buffer and
placed on ice for 10 minutes. The samples were then spun at 16,000 x g for 10
minutes and the supernatant (i.e. cytosolic fraction) was collected and placed into
a separate microcentrifuge tube. 1 ml of lysis buffer was added to the pellet (i.e.
membrane fraction) and 900 μl of lysis buffer was added to the supernatant
fraction. Following incubation at 4°C for 20 minutes, 3 μl of anti-CTA antibody
was added to each 1 ml fraction and incubated on a rocker at 4°C. Following an
overnight incubation, 30 μl of a protein A slurry prepared by the manufacturer’s
protocol was added to each fraction and incubated on a rocker at 4°C. Following
a 2 hour incubation, the samples were centrifuged for 5 minutes at 5,000 x g.
The pelleted beads were washed 2 times with 1 ml NDET and once with 1 ml of
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water. 50 μl of 1X sample buffer was added to each pellet. The samples were
run on a 15% SDS-PAGE gel and dried to filter paper using a Bio Rad gel dryer.
The dried gels were placed in a PhosphoImager cassette for 4 days and
analyzed using a Storm 840 Phospho-Imager and Image Quant software.
Background was subtracted from all samples prior to data calculations.
Percentage of cytosolic CTA1 was defined as the supernatant divided by pellet
plus supernatant (% cytosol = sup/[pellet+sup]).

2.12 Generation and Maintenance of Vero-d2EGFP Cell Line
Vero cells were seeded to 6 well plates so that they would be at ~75%
confluency after an overnight incubation. The cells were then transfected with
the d2EGFP plasmid. The cells were incubated overnight at 37°C and then lifted
from the 6-well plate with 0.25 ml of trypsin / EDTA in PBS. The cell suspension
was supplemented with 0.75 ml complete media, and 20% of the diluted cell
suspension was seeded to a 10 cm dish containing 10 ml of complete media.
Five 10 cm dishes were seeded in this manner. After growing overnight on the
10 cm dish at 37°C, the media was replaced with complete media containing 1
mg/ml of geneticin. The geneticin-containing media was replaced every three
days until numerous individual colonies could be seen on the 10 cm dish. Each
individual colony was lifted from the 10 cm dish and seeded in a well of a 24-well
plate. When the cells reached confluency in the 24-well plate, they were lifted
with trypsin / EDTA in PBS and transferred to a 6-well plate. When the cells
reached confluency in the 6-well plate, they were lifted again and transfered to a
10 cm dish. Each 10 cm dish, which represented a single clone from the original
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selection dish, was lifted and sorted individually using a FACScalibur cell sorter
to isolate the 10% of cells with highest fluorescent output. These cells were then
reseeded to a 10 cm dish and maintained by the addition of 1 mg/ml Geneticin
during each passage. The subclone with the highest fluorescent signal after this
process was used for all of our studies. The EGFP signal from multiple clones
could be detected with an epifluorescence microscope during the serial passages
from 24 well plate to 6 well plate to 10 cm dish, but cell sorting was necessary to
isolate a clone with suitable EGFP expression for the toxicity assays.

2.13 Toxicity Assay – Vero-d2EGFP
Vero-d2EGFP cells and the parental Vero cells were lifted and resuspended at final concentrations of 1,000,000 cells /ml. 100 µl of cell
suspensions were added to each well of a 96-well black bottom plate. The cells
were then incubated at 37°C for 48 hours. Media was removed from the cells
and replaced with the appropriate toxin-containing serum-free media and
incubated overnight at 37°C. Toxin-containing media was removed and the cells
were washed once with PBS. 100 µl PBS was added back to the wells prior to
reading the fluorescent signal. Fluorescence was read at an excitation of 485/20
nm and an emission of 528/20 nm using a Synergy 2 plate reader. Fluorescence
measurements are background subtracted from parental Vero cell and the data is
expressed as a percentage of the maximal signal from unintoxicated control
cells.

28

2.14 SPR Sensor Slide Generation
Gold-plated glass slides with a self-assembled monolayer, purchased from
Reichert, were activated by perfusing an EDC-NHS activation buffer for 10
minutes. The activated plate was then washed for 5 minutes with PBS (pH7.4)
containing 1% Triton X-100 (PBST). Antibody was perfused over the activated
sensor slide at a dilution of 1:2,000 in PBST for 15 minutes. Unbound antibody
was washed off the sensor slide with a 5 minute PBST wash. Ethanolamine was
perfused over the sensor slide for 3 minutes to cap any unbound tethers on the
gold plated plate. All perfusions were at a flow rate of 5 μl/min

2.15 SPR Analysis
PBST was perfused over the antibody bound sensor slide for 5 minutes to
establish a baseline reading. Experimental samples were perfused over the antibody bound sensor slide. Following each experimental condition, bound ligand
was removed for the sensor slide by washing the slide with PBST at pH 6.0.
Reichert Labview software was used for data collection.
For the translocation assays, the cytosolic pools generated were diluted in
HCN buffer to a volume of 1 ml. The 100 μl sample generated from the digitonin
permeabilization was too small to run through the SPR instrument. CTA1
standards were were diluted in HCN buffer for the translocation assay. Secretion
assays required all samples to be standardized to contain 5% glycerol in order to
eliminate any effects that glycerol might have on the detection by the SPR
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instrument. CTA1 standards were diluted in 5% glycerol for the secretion assays.
All solutions were perfused over the sensor slide at a flow rate of 5 μl/min.

2.16 Chemicals and Reagents
Sigma Aldrich (St. Louis, MO)
Calcium Chloride (CaCl2)
Ethylenediaminetetraacetic Acid (EDTA)
Leupeptin
N-ethyl maleimidie (NEM)
Niaproof-4 (NP-40)
Pepstatin
Phenymethylsulfonyl Flouride (PMSF)
Potassium Chloride (KCl)
Protease Inhibitor Cocktail
Protein A
Tetramethylethylenediamine (TEMED)
Thermolysin
Trichloroacetic Acid (TCA)
Fisher Scientific (Pittsburgh, PA)
2-Mercaptoethanol (β-ME)
Deoxycholic Acid
Ethanol 200 proof (EtOH)
Gel Code Blue Stain Reagent
Glycerol
Hydrochloric Acid (HCl)
Magnesium Cholride (MgCl2)
Methanol (MeOH)
Sodium Acetate (NaCH3COO)
Sodium Chloride (NaCl)
Sodium Hydroxide (NaOH)
Sodium Phosphate Dibasic Anhydrous (Na2HPO4)
Sodium Phosphate Dibasic Heptahydrate (Na2HPO4·7H2O)
Sodium Phosphate Monobasic Anhydrous (NaH2PO4)
Sodium Phospate Monobasic Monohydrate (NaH2PO4·H2O)
Tris Base
Tryptone
Tween-20
Invitrogen (Carlsbad, CA)
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Antibiotic-Antimycotic
Dulbecco’s Modified Eagle Medium (DMEM)
Geneticin
Ham’s F-12
Lipofectamine
Trypsin/EDTA
Amresco (Solon, OH)
Ammonium Persulfate (APS)
Bromophenol Blue
Glycine
HEPES
Methionine
Sodium Dodecyl Sulfate (SDS)
Tris-Cl
Triton X-100
Calbiochem (La Jolla, CA)
Adenodine Triphosphate (ATP)
Digitonin
Bio Rad (Hercules, CA)
40% Acrylamide /Bis Solution
Extra Thick Filter Paper
BostonBiochem (Cambridge, MA)
20S Proteasome
Beckman Coulter (Fullerton, CA)
Scintillation Fluid
Perkin Elmer (Waltham, MA)
[35S] Methionine
Alpha Biosciences (Baltimore, MD)
Yeast Extract
Atlanta Biologicals (Lawrenceville, GA)
Fetal Bovine Serum
Millipore (Billerica, MA)
Immobilin (PVDF)
BD Biosciences (San Jose, CA)
Skim Milk
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GE Healthcare (Piscataway, NJ)
BioTrak [125I] cAMP Assay Kit

2.17 Toxins
List Biological Laboratories (Campbell, CA)
Cholera Toxin, Holotoxin
Diptheria Toxin
Exotoxin A
Heat Labile Toxin
Sigma Aldrich (St. Louis, MO)
Exotoxin A
Shiga Toxin (SLT-2)
Calbiochem (La Jolla, CA)
Cholera Toxin, A subunit
Vector Laboratories (Burlingame, CA)
Ricin
2.18 Antibodies
Stressgen (Ann Arbor, MI)
Rabbit α-Hsp90
Rabbit α-PDI
Sigma Aldrich (St. Louis, MO)
Rabbit α-CTA
Jackson Immunoresearch (West Grove, PA)
Rabbit α-HRP
2.19 Equipment
Bio Rad (Hercules, CA)
Bio Rad Power Pac Basic
Bio Rad Power Pac HC
Model 853 Gel Dryer
Trans-Blot SD Semi-Dry Transfer Cell
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Beckman Coulter (Fullerton, CA)
Gamma Counter???????
LS 6500 Multi Purpose Scintillation Counter

GE Healthcare (Piscataway, MJ)
Äkta purifier
Storm 840 Phospho-Imager
BD Bioscience (San Jose, CA)
FACScalibur Cell Sorter
BioTek Instruments (Winooski, VT)
Synergy 2 Plate Reader
2.20 Other Materials
Grenier Bio One
6-well flat-bottom tissue culture plates
24-well flat-bottom tissue culture plates
96-well black, flat-bottom tissue culture plates
GE Healthcare (Piscataway, MI)
GSTrap HP (GST glutathione column)
American Type Culture Collection
Chinese Hamster Ovary (CHO) cells
HeLa cells
Vero cells
Invitrogen (Carlsbade, CA)
d2eGFP plasmid
pcDNA 3.1 plasmid
2.21 Buffers
Phosphate Buffered Saline (PBS), 10x
82.3 g Na2HPO4 (0.58M)
23.5 g NaH2PO4 (0.17M)
40 g NaCl (0.69M)
H2O to 1 liter
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Tris-Buffered Saline (TBS), 10x
24.24 g Tris-Cl
5.56 g Tris Base
80.1 g NaCl
H2O to 1 liter

Transfer Buffer
100 ml 10x SDS-Electrophoresis Running Buffer
200 ml MeOH
600 ml H2O
SDS-Electrophoresis Running Buffer, 10x
30.2 g Tris Base
144 g Glycine
10 g SDS
H2O to 1 liter
SDS sample buffer, 4x
50 ml 4x Tris-Cl/SDS pH 6.8
40 ml Glycerol
8 g SDS
2 mg bromophenol blue
100 mM 2-mercaptoethanol (7µl of 14.3 M ß-ME /ml of 4x buffer)
Lysis Buffer
25 mM Tris-Cl pH 7.4
20 mM NaCl
1% Deoxycholic Acid
1% Triton X-100
1 mM Phenylmethylsulfonyl fluoride (PMSF)
1 µg/ml Pepstatin
1 µg/ml Leupeptin
NDET
1% NP-40
0.4% Deoxycholic Acid
5 mM EDTA
10 mM Tris-Cl, pH 7.4
150 mM NaCl
Sodium Phosphate Buffer, 0.1 M
Solution A: 27.6 g NaH2PO4·H2O per liter (0.2 M)
Solution B: 53.65 g Na2HPO4·7H2O per liter (0.2 M)
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100 ml of pH 7.0 buffer add 39.0 ml of solution A and 61 ml of solution B
HCN Buffer
50 mM HEPES, pH 7.5
150 mM NaCl
2 mM CaCl2
10 mM N-ethyl maleimide (NEM)
1:20 dilution of Protease Inhibitor Cocktail
20S Proteasome Assay Buffer, 2x
100 mM HEPES, pH 7.5
20 mM MgCl2
200 mM KCl
0.2 mM CaCl2
GST Protein Purification Buffer
100 mM KCl
20 mM Tris-Cl, pH 7.5
5 mM MgCl2
LB Broth
10g Tryptone
5 g Yeast Extract
5 g NaCl
H20 to a liter
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CHAPTER 3 STRUCTURAL AND FUNCTIONAL INTERACTIONS
BETWEEN CTA1 AND HEDJ
3.1 Introduction
Our model proposes that CTA1 will be treated as a typical ERAD
substrate. After arrival in the ER, CTA1 dissociates from the rest of the
holotoxin51,52,92. The thermal instability of CTA1 results in spontaneous
unfolding. In this partially unfolded state, CTA1 mimics a misfolded protein that
is recognized by ERAD for export and proteasomal degradation. BiP, an ER
protein known to be necessary for protein folding and assembly as well as retrotranslocation across the ER membrane93,94, has been shown to interact with
CTA195. BiP is an Hsp70 protein that requires ATPase activity for most of its
functions. HEDJ/ERdj3 is an ER luminal protein that promotes ATP hydrolysis
on BiP36. HEDJ binds to misfolded proteins and recruits BiP96. BiP then binds to
the protein, releasing HEDJ, and allows the substrate to reach a conformation
suitable for secretion36. Failure to fold correctly results in retro-translocation and
proteasomal degradation of the protein. BiP requires interaction with HEDJ for
ATPase activity. HEDJ has been shown to interact with the AB protein toxin
Stx97. Therefore, we predicted that HEDJ would interact with CTA1. A dominant
negative construct of HEDJ was created that altered its localization from the ER
lumen to the luminal surface of the ER membrane97. Transfection of Vero cells
with this dominant negative HEDJ construct resulted in decreased Shigatoxigenic
effects by preventing the toxin from moving from the ER to the cytosol. Here we
found that HEDJ also interacts with CT. Disruption of normal HEDJ function
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blocked the translocation of CTA1 to the cytosol and its subsequent cytotoxic
effects. Surface plasmon resonance (SPR) measurements showed that HEDJ
binds directly to the CTA1 subunit. Binding of HEDJ is conformation-dependent:
HEDJ was able to bind to the partially unfolded conformation of CTA1 at 37°C
but, at 10°C (a temperature that maintains CTA1 in a folded conformation), HEDJ
was not able to bind to the toxin. A protease sensitivity assay showed that HEDJ
binding had no effect on the stability of CTA1. HEDJ was instead responsible for
masking the hydrophobic residues of CTA1 to prevent aggregation. These
findings put HEDJ in an exclusive category as one of the few eukaryotic proteins
that interact with multiple toxins.

3.2 Effect of HEDJ on CT Intoxication
Previous work has shown that HEDJ is active in Stx intoxication and
regulates the function of BiP, which is involved in CT intoxication. To determine
if HEDJ is involved in CT intoxication, dose response curves were generated for
cell transfected with empty vector pcDNA3.1 (mock), wild type HEDJ (wt HEDJ or
HED2) and dominant-negative HEDJ (dnHEDJ or HED3). Increased cAMP
levels are the hallmark of CT intoxication, so we used CHO cells to measure the
amount of CT-induced cAMP in the presence or absence of the transfected
HEDJ constructs. Little difference in the cAMP levels between the mock
transfected (EC50 5 ng/ml) and HED2 transfected cells (EC50 10 ng/ml) was
observed (figure 3-1). In contrast, CHO cells transfected with HED3 produced
much less cAMP in response to CT intoxication and the EC50 was extended to
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100 ng/ml. Transfection with HED3 resulted in an EC50 approximately 10 times
higher than HED2 transfected cells and nearly 20 times higher than the mocktransfected control cells.
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Figure 3-1 Effect of HEDJ on CT Intoxication
CHO cells were either mock transfected or transfected with wtHEDJ (HED2) or
dnHEDJ (HED3). The transfected CHO cells were incubated for 2 hours with the
indicated concentrations of CT. cAMP levels were assessed using a cAMP
competition assay. Each condition was done in triplicate. Results are expressed
as percentages of the maximal CT response for all conditions ± standard error of
the mean for three separate experiments.
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3.3 Effect of HEDJ on CTA1 Translocation
The inhibitory effect of dnHEDJ on Stx toxicity is due to the retention of
Stx in the ER97. ER to cytosol translocation assays were performed in order to
determine whether dnHEDJ had a similar effect on CT. CHO cells were cotransfected with ssCTA1 and either pcDNA3.1, HED2 or HED3. The ssCTA1
plasmid encods a CTA1 construct with a signal sequence that localizes the
protein in the ER. Transfected cells were then methionine starved for 60 minutes
at 37°C. The methionine free media was removed and replaced with 150 μCi
[35S] methionine/ml. Following a 60-minute incubation at 37°C, the cells were
selectively permeabilized using digitonin to isolate the cytosolic fraction
(supernatant) from all membrane bound organelles (pellet). Control experiments
were performed to ensure that the ER resident protein PDI remained in the pellet
fractions of all transfected cells. Hsp90, a cytosolic protein, was shown to remain
localized to the cytosolic fraction in all transfected cells. PhosphoImager analysis
was used to quantitfy the change in translocation of CTA1 in the presence of
wtHEDJ and dnHEDJ. All samples were normalized to the highest transfected
condition (ssCTA1 with pcDNA3.1). The cytosolic fractions were expressed as a
percentage of the control condition (pcDNA 3.1). CHO cells co-transfected with
ssCTA1 and wtHEDJ resulted in a 40% decrease in translocation of CTA1 from
the ER to the cytosol while dnHEDJ resulted in a 66% decrease in CTA1
translocation (figure 3-2). These results indicated that disruption of HEDJ
function results in decreased translocation from the ER to the cytosol.
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Figure 3-2 Effect of HEDJ on CTA1 Translocation
a) CHO cells were co-transfected with ssCTA1 and either mock (pcDNA3.1)
wtHEDJ (HED2) or dnHEDJ (HED3). Transfected CHO cells were methionine
starved for 60 minutes and then incubated with 150μCi [35S] methionine/ml for 60
minutes. Selective permeabilization of the plasma membrane with digitonin was
used to separate cell extracts into either cytosolic (supernatant, S) or membrane
bound (pellet, P) fractions. PhosphoImager analysis established the relative
percentages of cytosolic CTA1. One of two representative experiments is
shown. b) Western blot analysis established the distribution of the cytosolic
marker Hsp90, the ER marker PDI.

41

3.4 Effect of Temperature on HEDJ Binding to CTA1
We have shown that HEDJ has a functional role in CT intoxication. This
role could involve HEDJ by direct binding to CTA1 or by an indirect mechanism
through the HEDJ regulation of BiP function. In order to determine if HEDJ was
capable of binding directly to CTA1, we performed an SPR in vitro binding assay.
Purified GST-HEDJ was flown over an SPR sensor chip coated with an antiHEDJ antibody. The GST tag was removed from the bound GST-HEDJ with
PreScission Protease. CTA1-His6 was perfused over the HEDJ plate at various
temperatures. At 37°C, a positive signal indicating HEDJ binding to CTA1 was
seen (figure 3-3). In contrast, at 10°C there was no signal, indicating that HEDJ
did not bind to CTA1. Intermediate levels of binding were seen at 25°C and 33°C
(figure 3-3). HEDJ binding to CTA1 thus correlates to the folding state of the
subunit. At 37°C in the ER, CTA1 is in a partially unfolded conformation
permitting HEDJ binding. At temperatures below 37°C CTA1 retains more of its
native folded conformation that impedes HEDJ binding. To confirm that the
conformational change to CTA1 was the key feature for interaction between
HEDJ and CTA1, we perfused CTA1 in the presence of perfusion buffer at pH
6.0 or containing 10% glycerol. Both of these conditions have been shown to
stabilize CTA1 structure and prevented CTA1 from binding to the HEDJ sensor
slide (figure 3-3b). Completely denatured CTA1 in the presense of perfusion
buffer at pH 6.0 or containing 10% glycerol was capable of binding HEDJ (figure
3-3c). These data support our model of that A chain instability is the trigger for
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toxin-ERAD interactions. Upon arrival in the ER and dissocation from the B
subunit, CTA1 spontaneously unfolds and mimics a terminally misfolded protein.
ER chaperones target the toxin for export and proteosomal degradation. Thus,
toxin-ERAD interactions behave in the same way that normal ERAD substrates
would interact with ERAD chaperones.
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Figure 3-3 Effect of Temperature on HEDJ Binding to CTA1
SPR analysis was used to determine if HEDJ could bind CTA1 at various
temperatures. Purified HEDJ was bound to an SPR sensor slide. a) His-tag
CTA1 was perfused over the HEDJ sensor slide at 10°C, 25°C, 33°C and 37°C.
One of two replicate experiments shown. b) His-tag CTA1 in perfusion buffer at
pH 6.0 or perfusion buffer containing 10% glycerol. c) Denatured CTA1 in
perfusion buffer at pH 6.0 or perfusion buffer containing 10% glycerol perfused
over a HEDJ sensor slide. The arrow indicates when sample was exchanged for
perfusion buffer without ligand. The same SPR sensor slide was used for all
three panels.
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3.5 Effect of HEDJ on CTA1 Protease Sensitivity
Results from the SPR in vitro binding assay revealed that HEDJ binds to
the unfolded conformation that CTA1 assumes at 37°C. To determine if HEDJ
binding alters the structure of CTA1, we performed an in vitro protease sensitivity
assay. Thermolysin is a protease that hydrolyzes bonds on the N-terminal side
of hydrophobic amino acids. Exposed hydrophobic amino acids are a hallmark of
an unfolded protein. Due to the preference for hydrophobic amino acids,
thermolysin can be used as an indirect measure of protein folding. Samples of
purified HEDJ were incubated with reduced CTA1/CTA2 heterodimers using the
protocol for the protease sensitivity assay (see Chapter 2.7). Thermolysin
addition occurred at 4°C, after pre-incubation at various temperatures, to ensure
CTA1 degradation was only the result of temperature-induced conformational
changes to the toxin. Samples were then resolved by SDS-PAGE with
Coomassie staining. The CTA1 subunit remains in a conformation protected
from proteolytic cleavage at 4°C, 25°C and 33°C (figure 3-4a). At 37°C, CTA1
partially unfolds and becomes susceptible to proteolytic cleavage by thermolysin
(figure 3-4a). In the presence of HEDJ, the pattern of CTA1 protease sensitivity
did not change (figure 3-4b). This data suggested that HEDJ does not stabilize
or destabilize CTA1. We would expect that, if HEDJ was unfolding CTA1,
degradation would occur at lower temperatures in the presence of HEDJ.
Conversely, we would expect that, if HEDJ were acting as stabilizing agent on
CTA1, degradation would not occur until 41°C if at all.
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The current model for CTA1 translocation asserts that certain ERAD
proteins utilize novel functions in CT intoxication. It is believed that PDI, a
protein normally responsible for the cleavage and rearrangement of disulfide
bonds, acts as an unfoldase during CT intoxication. Our model suggests that
ERAD proteins maintain their normal functions during CT intoxication. The
normal role for function of HEDJ is to recognize surface exposed hydrophobic
residues, a hallmark of unfolded proteins, and recruit BiP in order to facilitate
proper folding or translocation. The binding or masking of surface exposed
hydrophobic residues prevents aggregation of proteins. An ANS assay
performed by Dr. Kathleen Nemec confirmed that HEDJ was masking the surface
hydrophobic residues of CTA1 that were exposed at 37°C. ANS is a fluorescent
dye that undergoes a blue shift when it binds to surface exposed hydrophobic
residues, and this increases its fluorescent intensity. In the presence of HEDJ, a
temperature dependent increase in ANS signal for unfolded CTA1 did not occur.
This indicated that HEDJ masked the surface exposed hydrophobic residues of
CTA1 that were otherwise available for ANS binding.
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Figure 3-4 Effect of HEDJ on CTA1 and α-Casein Protease Sensitivity
Samples of reduced CTA1/A2 at 1 μg/ml in the absence (a) or presence (b) of 1
μg/ml of purified HEDJ were incubated in 20 mM sodium phosphate buffer pH 7.4
for 1 hour at the given temperatures. Equimolar concentrations of CTA1 The
samples were then shifted to 4°C and exposed to thermolysin for 1 hour.
Samples were visualized by SDS-PAGE and Coomassie staining. HEDJ is
barely visible in the “pure” sample (i.e. not treated with thermolysin) because it
does not stain well with Coomassie, and it is not visible in the thermolysin treated
samples because HEDJ is susceptible to thermolysin degradation.
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3.6 Discussion
Cholera toxin is an ADP-ribosylating toxin that constitutively activates Gsα.
The activation of the G protein results constant production of cAMP by adneylate
cyclase. cAMP is a cellular secondary messenger that opens Cl- channels and
prevents the adsorbtion of Na+. The build up of Na+ and Cl- ions causes an efflux
of water in order to achieve osmotic balance, thus resulting in perfuse watery
diarrhea. In order for CT to reach the G protein, it must gain access to the
cytosol. CT, however, lacks intrinsic pore forming capabilities of other toxins
such as DT or the anthrax toxins (lethal and edema). CT is trafficked to the ER
in retrograde fashion where it is capable of exploiting the ERAD pathway44,65-67.
BiP is active in the proper folding and assembly of nascent secretory proteins as
well as ERAD. HEDJ is an ER luminal Hsp40 chaperone that facilitates the
hydrolysis of ATP to ADP by BiP36. HEDJ also directly binds to native unfolded
secretory proteins96. HEDJ has been shown to interact with Stx prior to Stx
translocation97. In an attempt to further characterize the translocation event of
CT, we examined the effects of HEDJ on CT intoxication, CTA1 translocation and
CTA1 structure. We demonstrated that transfection of CHO cells with dnHEDJ
prevented CT intoxication. The presence of dnHEDJ resulted in decreased
translocation of CTA1 into the cytosol. SPR analysis further demonstrated that
HEDJ interacts directly with CTA1. Based on these data, it is likely that CTA1 is
recognized as a terminally misfolded protein by HEDJ. HEDJ interacts with BiP,
which then transports the toxin to the translocon for export from the ER to the

48

cytosol. Thus, disruption of HEDJ function should prevent proper translocation
and inhibit intoxication.
Co-transfection translocation assays were conducted to determine if the
decreased toxicity was a result of decreased export across the ER membrane.
We utilized a plasmid based expression system of CTA1 with a signal sequence
for targeting to the ER. Phosphoimager analysis reveals that in the presence of
wild-type HEDJ, translocation of CTA1 to the cytosol was unaffected. However,
in the presence of the dominant-negative HEDJ, we show a decrease of CTA1 in
the cytosolic fraction of the translocation assay.
We wanted to ensure the effects we were seeing by the intoxication and
translocation assays were a result of the interactions between HEDJ and CTA1
and not a by-product of some other interaction such as HEDJ and BiP. Our SPR
data confirm that HEDJ binds directly to CTA1. HEDJ binds to misfolded
proteins. Based on our model that CTA1 is thermally unstable, we expected that
HEDJ binding would occur in a temperature-dependent manner. At temperatures
below 37°C, CTA1 remains in a folded conformation and HEDJ was unable to
effectively bind to the toxin. At 37°C and higher CTA1 is partially unfolded and
capable of being bound by HEDJ.
Our previous work has indicated that the trigger for ERAD-mediated
translocation is the global loss of CTA1 structure. We have reported that CTA1
spontaneously unfolds upon dissocation from the holotoxin. We have also
reported that stabilization of CTA1 via glycerol prevents translocation. It is
unclear what role HEDJ might have on CTA1 structure. Our protease protection
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assays reveal that HEDJ is not involved in the loss or stabilization of CTA1
structure. Degradation of CTA1 in the presence of purified HEDJ remained
unchanged from the degradation pattern of CTA1 alone. If HEDJ were
influencing CTA1 structure by unfolding the protein, we would have expected to
see degradation at the lower temperatures as well as the higher temperatures.
Conversely, if HEDJ stabilized CTA1, like glycerol, we would have expected to
see a resistance to thermolysin degradation at the higher temperatures. These
data suggest that HEDJ binds to unfolded CTA1 to prevent aggregation with
other misfolded proteins prior to the translocation event.

3.7 Future Directions
BiP activity is required for tranport from microsomes derived from the ER95.
Our data show that HEDJ binds to CTA1 during the course of intoxication.
Disruption of normal HEDJ activity results in decreased cAMP in CHO cells. It
has been suggested that HEDJ binds to target proteins first and subsequently
recruits BiP to the protein. It has also been suggested that hydrolysis of Bip by
HEDJ plays a role in the dissociation of HEDJ from target proteins. The exact
role of HEDJ in the translocation of CTA1 still needs to be clearly defined. We
believe that HEDJ recruits CTA1 to BiP. HEDJ hydrolyzes ATP-bound BiP to
ADP-bound BiP, which serves to stabilize the association between BiP and CTA1
and prevent CTA1 aggregation. Prevention of aggregation results a
conformation suitable for translocation to the cytosol. We believe that HEDJ acts
as a co-chaperone for BiP by actively delivering the HEDJ-bound CTA1 to BiP
and stimulating the ATPase activity of BiP. This activity allows BiP to attain a
50

closed conformation that stably associates with the unfolded conformation of
CTA1 and prevents aggregation. BiP is believed to maintain CTA1 in a
translocation competent state. Further experiments will be carried out in order to
determine the binding events between HEDJ, BiP and CTA1.
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CHAPTER 4 STABILIZATION OF CTA1 INHIBITS
TRANSLOCATION AND CELLULAR INTOXICATION
4.1 Introduction
CT binds to the cell surface receptor GM1, is endocytosed and trafficked to
the ER by retrograde vesicular transport44,65-67. In the ER, the holotoxin
dissociates into individual A and B subunits51,52,92. The catalytic CTA1 subunit
mimics a misfolded protein and is recognized by the ER quality control
mechanism, ERAD, and exported from the ER to the cytosol95,98-100. The
molecular mechanisms of this export process are poorly characterized. The
current model for CTA1 translocation is that upon entry into the ER, PDI binds to
CTA1 and actively unfolds the toxin52. In contrast, we conclude from our data
that the trigger for the CTA1 translocation event is a thermal denaturation that
occurs after CTA1 dissociates from the rest of the holotoxin. Previous work has
already demonstrated the temperature dependent conformational instability of
the CTA1 subunit101. According to our model, stabilization of the CTA1 subunit
will prevent translocation and subsequent intoxication. Glycerol is chemical
chaperone that stabilizes protein structure. Previous reports have indicated that
glycerol and other cryoprotective compounds provide resistance to three other
ERAD-exploiting toxins: ricin, exotoxin A (ETA) and Stx-2102,103. It has also been
demonstrated that chemical chaperones, such as glycerol, stabilize protein
structures and are commonly used to disrupt ERAD-substrate interactions104-108.
We show here that glycerol prevents the temperature-dependent loss of CTA1
tertiary structure, which blocks translocation and results in resistance to
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intoxication. We also show that stabilization of CTA1 with glycerol prevents its
degradation by the 20S proteosome. These results suggest a new therapeutic
approach for the prevention of cholera.

4.2 Effect of Glycerol on CTA1 Protease Sensitivity
To determine the effect of glycerol on CTA1 structure, we utilized the previously
described in vitro thermolysin protease sensitivity assay. Thermolysin cleaves
surface exposed hydrophobic residues and can thus be used as an indirect
measure of protein misfolding. A final concentration of 10% glycerol was used to
maintain consistency with previously reported uses of glycerol as an ERAD
disrupting compound. Based on our model of translocation, CTA1 spontaneously
unfolds at 37°C and is thus susceptible to cleavage by thermolysin. Samples of
the reduced CTA1/CTA2 heterodimer were incubated in the presence or absence
of 10% glycerol for 45 minutes at the given temperatures. To ensure that any
degredation effects are attributed to the folding state of CTA1, all samples were
transferred to ice before treatment with thermolysin. Treated samples were
resolved by SDS-PAGE with Coomassie staining. Figure 4-1a shows that our
reducing condition of 10 mM β-ME was sufficient for separation of CTA1 from
CTA2 in the absence or presence of 10% glycerol. Reduction conditions must be
present because the association of CTA1 with CTA2 is sufficient to provide some
conformational stability for CTA1101. In the absence of 10% glycerol, CTA1 is
resistant to thermolysin degradation when pre-incubated at temperatures up to
33°C (figure 4-1b). At a pre-incubation temperature of 37°C, CTA1 transitions to
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a protease sensitive state. In the presence of glycerol however, CTA1 remains
protease resistant when incubated at 37°C and 41°C (figure 4-1b). Glycerol was
unable to prevent the thermolysin-mediated proteolysis of α-casein, a protein
with very little tertiary structure (figure 4-1c). These results indicated that glycerol
prevents CTA1 from achieving a protease sensitive conformation at 37°C and
41°C. Degradation of α-casein in the presence of glycerol indicates that glycerol
does not have a direct inhibitory effect on thermolysin.
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Figure 4-1 Effect of Glycerol on CTA1 and α-Casein Protease Sensitivity
a) 1 μg of CTA1/A2 heterodimer was exposed to 10 mM β-ME in the presence or
absence of 10% glycerol for 5 minutes. Samples were run on a non-reducing
SDS-PAGE gel along with 1 μg of CTA1/A2 that was not exposed to β-ME (no
treatment). Samples were visualized by Coomassie staining. The 5 kDa CTA2
cannot be detected. Samples of the reduced CTA1/A2 (b) or α-casein (c) were
incubated in 20 mM sodium phosphate buffer pH 7.4 with or without 10% glycerol
for 1 hour at the given temperatures. The samples were shifted to 4°C and
exposed to thermolysin for 1 hour. Samples were visualized by SDS-PAGE and
Coomassie staining.
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4.3 Effect of Glycerol on CTA1 Translocation
Our model suggests that stabilization of CTA1 structure traps the protein in
a conformation not suitable for translocation. To test this model, we used a
translocation assay to monitor the distribution of CTA1 in the cytosol and ER of
untreated or glycerol-treated cells. HeLa cells were incubated on ice for 30
minutes in the presence of 1 μg/ml of CT. Cells were pulse labeled with CT at
4°C, a temperature that prohibits endocytosis. Unbound toxin was removed,
and the cells were allowed to incubate at 37°C for 2 hours in either in the
presence or absence of 10% glycerol. Digitonin was then used to selectively
permeabilize the cells and separate the cytosolic fraction from the
membrane/organelle fraction. We selectively permeablized control cells to
ensure that we could detect PDI, an ER chaperone, only in the
membrane/organelle fraction. We also probed for Hsp 90, a cytosolic protein that
should only be found in the cytosolic fraction. The selective permeabilization of
control cells showed that PDI was localized only in the membrane/organelle
fraction and that Hsp 90 was localized only to the cytosolic fraction (figure 4-2a).
These controls confirmed that selective permeabilization via digitonin can
distinguish cytosolic proteins from membrane/organelle proteins. Western blot
analysis revealed that CTA1 was found only in the membrane/organelle fraction
of pulse-labeled cells (figure 4-2a). The pulse-labeled cells represent the amount
of surface bound toxin available for endocytosis and thus a maximum signal.
Cells incubated at 37°C for 2 hours in the absence of glycerol allowed a portion
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of the surface-bound toxin to enter the cytosol (figure 4-2a). A decrease in the
cytosolic amount of CTA1 was detected in cells that were incubated at 37°C for 2
hours in the presence of 10% glycerol (figure 4-2a). These data demonstrate
that intoxication in the presence of 10% glycerol inhibited CTA1 translocation into
the cytosol.
SPR was used as an alternative method for detection of the cytosolic
CTA1. Samples were prepared following the same protocol as detailed above.
The cytosolic fractions were perfused over an SPR sensor chip coated with an
anti-CTA antibody. No signal was detected from the cytosolic fraction of
unintoxicated cells or from the cytosolic fraction of cells treated with Brefeldin A
(BfA) (figure 4-2b). BfA is a drug known to inhibit intracellular traffic109-111. Cells
treated with glycerol-free media generated a positive signal when analyzed
(figure 4-2b). In contrast, cells treated with 10% glycerol failed to elicit a positive
response (figure 4-2b). These data support the Western blot analysis data that
10% glycerol blocks translocation of CTA1 from the ER to the cytosol.
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Figure 4-2 Effect of Glycerol on CTA1 Translocation
HeLa cells were pulse labeled with 1 μg/ml of CT for 30 minutes at 4°C. The
cells were then chased for 2 hours at 37°C in media either containing or lacking
10% glycerol. Selective permeabilization of the plasma membrane with digitonin
was used to separate cell extracts into either cytosolic (supernatant, S) or
membrane bound (pellet, P) fractions. a) Western blot analysis established the
distribution of the cytosolic marker Hsp90, the ER marker PDI, and CTA1. One
of two experiments is shown. b) SPR analysis was used to detect the cytosolic
pool of CTA1 from treated (+ glycerol) and untreated (no treatment) cells. CTA1
standards were flown over the sensor chip as positive controls. One of four
experiments is shown. The arrow indicates when the sample was exchanged out
of the perfusion buffer. Bound samples were stripped from the sensor chip with a
5 min PBST wash at pH 6.0.
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4.4 Effect of Glycerol on Secretion from Intoxicated Cells
Properly folded ER proteins are packaged into vesicles for transport to the
Golgi apparatus and beyond. It is possible that the stabilization of the CTA1
structure is forcing the ER machinery to recognize CTA1 as a properly folded
protein ready for secretion. Treatment with 10% glycerol could therefore promote
secretion of the CTA1 subunit. To examine this effect, we used SPR analysis to
detect CTA1 in the extracellular media of cells intoxicated in the presence and
absence of 10% glycerol. A slight signal was detected when medium from
unintoxicated cells was perfused over an SPR sensor chip coated with an antiCTA antibody, indicating a small amount of non-specific binding. A positive
signal was detected when medium from intoxicated cells was perfused over the
sensor and an even stronger signal was detected for media samples from
intoxicated cells incubated with 10% glycerol (figure 4-3). These results
indicated that under normal intoxication conditions, a small amount of CTA1 is
secreted. This confirmed an earlier reported observation67. However, as we
hypothesized, stabilization of CTA1 structure by means of glycerol resulted in
much greater secretion. Analysis of the secretion samples was also conducted
using an SPR sensor chip coated with an anti-CTB antibody to ensure that the
signal from media samples was not holotoxin that had been released from the
cells. No signal was detected from the anti-CTB plate indicating that toxin in the
media did not contain the CTB subunit (data not shown). Together, these data
suggest that glycerol promotes secretion of the CTA1 subunit.
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It was possible that although glycerol was preventing the loss of structure
in vitro, it could be having an alternate effect in vivo. The secretion of CTA1 from
cells treated with 10% glycerol suggested that trafficking to the ER was not
altered. Dissociation of CTA1 from the rest of the holotoxin only occurs in the
ER. To further examine any alterations in trafficking, we monitored the secretion
of CTA1 from cells treated with BfA, and under this condition we were unable to
detect a positive signal from media in the presence or absence of 10% glycerol.
This indicates that CTA1 was not being released prior entering the ER since BfA
blocks trafficking from the endosomes to the Golgi. These results, taken
together, strongly suggest that glycerol-stabilized CTA1 is treated as secretory
cargo rather than an ERAD substrate.
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Figure 4-3 Effect of Glycerol on CTA1 Secretion from Intoxicated HeLa
Cells
HeLa cells were pulse labeled at 4°C for 30 minutes with 1 μg/ml of CT. The
cells were chased for 2 hours at 37°C in media either containing or lacking 10%
glycerol. Media samples from the cells were collected and analyzed by SPR with
an anti-CTA antibody sensor chip. CTA standards were flown over as controls.
One of four experiments is shown. The arrow indicates when sample was
exchanged for perfusion buffer. Bound sample was stripped from the chip with a
5 min PBST was at pH 6.0.

61

4.5 Effect of Glycerol on CT Intoxication
Treatment of HeLa cells with 10% glycerol appeared to block translocation
into the cytosol. The intracellular target of CTA1 is Gsα, a part of the
heterotrimeric G protein that is associated with the cytosolic surface of the
plasma membrane. The blockage of translocation into the cytosol should
therefore prevent CT intoxication. To evaluate the effects of glycerol on CT
toxicity, we monitored the cAMP levels in intoxicated cells treated with 10%
glycerol. Cells were intoxicated with varying concentrations of holotoxin for 2
hours. The cells exposed to 10% glycerol showed decreased cAMP levels when
compared to untreated cells (figure 4-4). The EC50 in the absence of glycerol
was approximately 5 ng/ml. In the presence of glycerol, the EC50 was
approximately 50 ng/ml, 10 times higher than in the absence of glycerol. These
observations demonstrate decreased toxicity of CT in glycerol treated cells. We
used a forskolin control to ensure glycerol was not directly inhibiting adenylate
cyclase, the down stream target of Gsα directly responsible for the production of
cAMP (data not shown). These results, combined with the data from the
Western blot and SPR secretion assays, showed that the glycerol-induced
inhibition of intoxication is most likely a result of a blockage of CTA1 translocation
to the cytosol.
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Figure 4-4 Effect of Glycerol on CT Intoxication
CHO cells were incubated for 2 hours with the indicated concentrations of CT in
media either lacking or containing 10% glycerol. cAMP levels were assessed
using a cAMP competition assay. Each condition was done in triplicate. Results
are expressed as percentages of the maximal CT response for all conditions ±
standard error of the mean for three separate experiments.
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4.6 Effect of Glycerol on CTA1 Degradation by the 20S Proteasome
The ERAD process utilizes the 26S proteasome to degrade terminally
misfolded proteins. This 26S proteasome is composed of two 19S caps
responsible for ubiquitin recognition and ATP-dependent unfolding and a single
20S catalytic core, which is the actual degradation machinery. In vitro, CTA1 is a
substrate for ubiquitin-independent degradation by the 20S proteasome101. To
determine if stabilization of CTA1 affected degradation by the 20S proteasome,
we incubated reduced CTA1/CTA2 with purified 20S proteasome for 0, 4, 8 and
20 hours in the presence or absence of 10% glycerol. Degredation of CTA1 was
detected as early as 3 hours in the absence of 10% glycerol (figure 4-5). With
the addition of 10% glycerol, degradation was reduced in samples incubated as
long as 20 hours (figure 4-5). Since the 20S proteasome is only capable of
degrading unfolded proteins, this suggests that glycerol maintains CTA1 in a
folded state. To ensure that glycerol was not directly altering the activity of the
20S proteasome, we incubated α-casein in the presence and absence of 10%
glycerol and detected no alteration in the degradation of α-casein. The
stabilization of CTA1 structure by glycerol therefore prevented its degradation by
the 20S proteasome.
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Figure 4-5 Effect of Glycerol on CTA1 Degradation by the 20S Proteasome
a) Reduced CTA1/A2 was incubated at 37°C with 100 nm of the 20S proteasome
in the absence or presence of 10% glycerol. Samples were collected at the
indicated time points and visualized by SDS-PAGE and Coomassie staining. b)
Identical steps were performed with α-casein as the sample protein.
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4.7 Discussion
The current model for CTA1 translocation suggests that the A subunit is
thermally stable and requires active unfolding in the ER to interact with the ERAD
machinery. It was originally thought that the trigger for this unfolding event was
the C-terminal hydrophobic region of CTA1. However, recent work has shown
that the C-terminal region of the toxin is not necessary for translocation to the
cytosol112. We propose that the trigger for ERAD is the thermal instability of
CTA1. Our model suggests that the loss of CTA1 structure that follows
dissocation from the holotoxin results in a protein that the ERAD machinery
recognizes as misfolded and attempts to eliminate from the ER. Based on this
model we would predict that stabilization of the CTA1 structure would prevent
translocation of the toxin to the cytosol.
Thermolysin assays were used to show that CTA1 is a thermally unstable
protein. At 37°C CTA1 was in a conformation sensitive to proteolytic cleavage by
a protease that only affects surface exposed hydrophobic residues. In contrast,
samples treated with 10% glycerol remained resistant to thermolysin cleavage
even at 41°C. Furthermore, the 20S proteasome is only capable of degrading
unfolded substrates. CTA1 is a substrate for degradation by the 20S proteasome
at 37°C, but we showed that stabilization of CTA1 by glycerol conferred
resistance to 20S protesomal degradation. The inhibition of CTA1 degradation in
the presence of glycerol suggests that the loss of structure is responsible for
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targeting to the 20S proteasome. Both assays utilized α-casein as controls to
ensure that glycerol was not affecting the activity of the proteases.
Glycerol treatment prevented CTA1 from translocating from the ER to the
cytosol. As expected, the inhibition of translocation resulted in a decrease in
toxicity. These effects reveal the importance of thermal instability during the
normal course of intoxication. The trigger for ERAD therefore is not due to the
presence of a specific domain, but is derived from the loss of structure. As a
consequence of stabilization, CTA1 is not recognized as a misfolded protein by
ERAD. Instead the thermal stabilization by glycerol promotes secretion of the
toxin to the extracellular medium. Protection of the cell from intoxication via
glycerol not only prevents any harmful effects that may be generated due to toxic
activity but also prevents accumulation of the toxin in the ER. This latter effect
would protect the cell from any harmful effects that might be generated by ER
stress responses to toxin build up in the ER. Also, secreted toxin results in free
CTA1 in the extracellular medium that cannot rebind/reintoxicate cells. Given
these results, thermal stabilization makes a promising target for ant-toxin
therapueitcs.

4.8 Future Directions
Our data demonstrate that stabilization of CTA1 prevents its translocation to
the cytosol and even promotes its secretion to the extracellular space. Exposure
to 10% glycerol is not a viable therapeutic option. However, we have provided
proof-of-principle that the thermal stabilization of CTA1 is a novel target for antitoxin therapeutics. This suggests that other potential chemical chaperones can
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stabilize CTA1 without the harmful side effects would be a viable therapeutic.
Other ER translocating toxins also appear to have thermally unstable A chains,
so the stabilization of these subunits is a potential target for multi-toxin
therapeutics.
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CHAPTER 5 NOVEL CELL-BASED ASSAY TO DETECT
INHIBITORS OF TOXIN ACTIVITY
5.1 Introduction
STEC is an enteric pathogen known to cause hemorrhagic colitis and HUS.
Ec0157 is the most common serotype of the STEC pathogens. It has been
reported that Ec0157 causes approximately 73,000 cases of food- or waterborneillness per year in the United States76. The major virulence factors of Ec0157 are
the Shiga toxins it produces (ST-1 and ST-2). These toxins inhibit protein
synthesis by inactivating the ribosome through cleavage of the N-glycosidic bond
of A4324. These toxins are also involved in the development of HUS75,77. It is
believed that inactivation of the toxins would help to prevent HUS, for which
supportive care is currently the only treatment. Here, we describe a novel cellbased assay for the detection of inhibitors of toxin activity by using Vero cells that
express a destabilized variant of the green fluorescence protein (d2EGFP). This
assay monitors the Stx-induced inhibition of protein synthesis by measuring the
loss of fluorescence output from the cells. A panel of natural compounds was
screened for anti-Stx activity. Using our Vero-d2EGFP assay, we found that
grape seed and grape pomace extracts had an inhibitory effect on the ability of
Stx to block protein synthesis in Vero cells.
Previous chapters have indicated that inhibitors of toxin activity can target
ER chaperones or the toxins themselves. Those studies were all targeted
studies looking at specific sites for potential therapeutics. Here, we wanted to
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conduct a screen of compounds that would yield untargeted/unbiased potential
inhibitors.
Most of the current methods for detecting toxin activity are not useful for
high-throughput screening. Radiolabel assays are more commonly used but
require the use of radioisotopes and specialized training83,113. Radiolabel assays
are also more laborious and are limited by the number of replicates that can be
performed in each assay. Many non-radioactive assays exist; however, these
assays typically require high concentrations of toxin and/or commercially
purchased kits making these types of assays much more cost prohibitive74,114,115.
Zhao and Haslam developed a system similar to the one described here116. In
their assay they monitor the loss of luciferase light output after exposure to Stx.
A high-throughput screen has been executed using the luciferase-based assay.
While the luciferase assay is very similar to the Vero-d2EGFP assay we
describe, the luciferase assay requires additional preparatory steps, time and
processing of data.
Stx activity in mammalian cells results in the inhibition of protein synthesis.
Standard radiolabel assays utilize a radioactive amino acid to incorporate into
newly synthesized proteins. The decrease in protein synthesis is monitored by a
decrease in radioactivity: since new proteins cannot be synthesized they are
incapable of incorporating the radiolabeled amino acid. The Vero-d2EGFP assay
works on the same principal, but, rather than using radioactive amino acids as
the reporter, we use a destabilized variant of EGFP. The Vero cells stably
express the d2EGFP reporter construct, which results in constant production of
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the d2EGFP protein and thus constant fluorescence that can be seen by
fluorescence microscopy. The destabilized variant of the construct contains a
PEST sequence that targets the protein for degradation resulting in a 2-hour halflife within the cell. If protein synthesis is inhibited, over time the fluorescence
signal will decrease which can be monitored using a fluorescence plate reader,
amenable for a high-throughput screen.

5.2 Effect of ST-2 on Vero-d2EGFP Fluorescence and Overall Protein
Synthesis
The Vero-d2EGFP cell line was generated as described in Chapter 2. After
generation of the cell line, fluorescence microscopy was used to show
expression of the d2EGFP construct (figure 5-1). Vero-d2EGFP cells were
treated with various concentrations of ST-2 for 16 hours at which point toxicity
was assessed using a standard radiolabel assay to monitor protein synthesis
(figure 5-2 closed circles) or using our Vero-d2EGFP assay (figure 5-2 closed
squares). ST-2 was used because it has been demonstrated that it is much
more potent than ST-190. Both assays showed a dose-dependent response in
the loss of protein synthesis (figure 5-2). Both assays established an EC50 for
ST-2 of 100 pg/ml, with the detection of protein synthesis inhibition with as little
as 10 pg ST-2/ml. In chapter 4 we showed that treatment of CHO cells with 10%
glycerol confers resistance to CT. Previous studies have also shown that
treatment of cells with 10% glycerol confers resistance to the plant toxin ricin102
and the plasmid-encoded toxin of enteroaggregative E. coli117. We therefore
used glycerol as a control to show that our d2EGFP assay could detect toxin
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inhibitors. Treatment of cells with 10% glycerol resulted in a fluorescent signal
approximately two times higher than cells co-incubated with 100 ng/ml of ST-2.
Glycerol therefore blocks Stx activity, and the Verol-d2EGFP assay can be used
to detect toxin inhibitors.
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Figure 5-1 Fluorsecence Intensity of Vero-d2EGFP Cells
Vero-d2EGFP cells were grown on glass coverslips incubated for 16 hours.
Flourescence image is shown.
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Figure 5-2 Effect of ST-2 on Vero-d2EGFP Fluorsecence and Protein
Synthesis
Vero-d2EGFP cells were incubated for 16 hours with the indicated
concentrations of ST-2. Protein synthesis and fluorescence were measured
using separate samples of Vero-d2EGFP cells. The maximal signal was set to
the unintoxicated samples. Data reported are for the means ± standard error of
the means of at least three independent experiments with triplicate samples for
each condidtion. The open square represents two experiments in which Verod2EGFP cells were co-incubated with 100 ng/ml of ST-2 and 10% glycerol.
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5.3 Use of the Vero-d2EGFP Assay to Screen for Stx Inhibitors
Plant compounds have been previously demonstrated to inhibit the
cytopathic effects of CT118-120.

We used the Vero-d2EGFP assay to screen a

panel of plant compounds for anti-Stx activity. The Vero-d2EGFP cells were coincubated with select compounds and varying concentrations of ST-1- and ST-2containing media. We screened the compounds in two rounds. The first round
of compounds included apple skin extract, chlorogenic acid, N-Acetyl-L-cysteine,
epigallocatechin gallate, theaflavin-3-gallate, trans-cinnamaldehyde, green tea
polyphenols and oregano oil. We were unable to detect any inhibition of toxin
activities from these compounds. The second round of screens using red wine
concentrate, caffeic acid, grape pomace and grape seed extract resulted in two
promising compounds. Grape pomace and grape seed extract were capable of
inhibiting the Stxs present in the cultured supernatant from E. coli strain RM1697,
a strain that produces both ST-1 and ST-2 (figure 5-3 open squares and circles
respectively). Conversely, caffeic acid and red wine concentrate were unable to
inhibit toxin activity (figure 5-3 closed diamond and circle respectively). The
concentration of toxin-containing media required to reach the EC50 was nearly
7,000 fold greater when co-incubated with grape seed extract than that required
for control cells. The toxin EC50 in the presence of grape pomace was nearly 200
fold greater than the untreated control cells.
It is possible that the results we were seeing were due to proteasomal
inhibition. If we blocked proteasomal degradation we would block the
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degradation of the d2EGFP protein resulting in prolonged fluorescence. We
therefore verified the Vero-d2EGFP results using an independent toxicity assay
monitoring overall protein synthesis levels with [35S] methionine. The Verod2EGFP cells were incubated with toxin for 2 hours, to detect any subtle antitoxin
effects that might have been missed during the 16-hour intoxication with the
Vero-d2EGFP assay. Results from the radiolabel toxicity assay matched the
results of the Vero-d2EGFP assay for both caffeic acid and red wine concentrate:
neither assay indicated anti-toxic activities for those compounds (figure 5-4).
Consistent with the Vero-d2EGFP assay, grape seed extract and grape pomace
extract both showed anti-toxin activity. These data demonstrate that both grape
seed and grape pomace extracts were Stx inhibitors and that our Vero-d2EGFP
assay can be used to detect both the presence of Stx and inhibitors of toxin
activity. Using the Vero-d2EGFP screen, both grape pomace extract and grape
seed extract were tested for their ability to inhibit intoxication of ETA and ricin,
two other AB protein toxins that inhibit protein synthesis. Both compounds were
capable of inhibiting ETA (figure 5-5)and ricin (figure 5-6) intoxication.
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Figure 5-3 Effect of Plant Compounds on Fluorescence Output from Stxtreated Vero-d2EGFP Cells
Cells were incubated for 16 hours with plant compounds and the indicated
dilutions of cell-free cultured supernatant from Ec0157 strain RM1697 that
produces both ST-1 and ST-2. Fluorescence output was recorded with a plate
reader. Cells were co-incubated with no compound, 0.5 mg/ml of caffeic acid, 1
mg/ml of red wine concentrate, 0.5 mg/ml of grape pomace extract or 0.5 mg/ml
of grape seed extract. Data shown are the averages ± standard deviations of the
means of three independent experiments with triplicate samples for each
condition.
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Figure 5-4 Effect of Plant Compounds on Protein Synthesis in Stx-treated
Vero-d2EGFP Cells
Protein synthesis levels were measured in Vero-d2EGFP cells that were coincubated with the indicated plant compounds and ST-2 concentrations for 2
hours. Cells were incubated with no compound, 1 mg/ml caffeic acid, 1 mg/ml of
red wine concentrate, 0.5 mg/ml grape pomace extract, or 0.1 mg/ml of grape
seed extract. Data shown are the averages ± standard error of the means of at
least 4 independent experiments with triplicate samples.
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Figure 5-5 Effect of Plant Compounds on Fluorescence Output from ETAtreated Vero-d2EGFP Cells
Cells were incubated for 16 hours with plant compounds and the indicated
dilutions of purified ETA. Fluorescence output was recorded with a plate reader.
Cells were co-incubated with no compound 0.5 mg/ml of grape pomace extract,
or 0.5 mg/ml of grape seed extract. Data shown are the averages ± standard
errors of the means of four independent experiments with triplicate samples for
each condition.
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Figure 5-6 Effect of Plant Compounds on Fluorescence Output from ricintreated Vero-d2EGFP cells
Cells were incubated for 16 hours with plant compounds and the indicated
dilutions of purified ricin. Fluorescence output was recorded with a plate reader.
Cells were co-incubated with no compound 0.5 mg/ml of grape pomace extract or
0.5 mg/ml of grape seed extract. Data shown are the averages ± standard
errors of the means of four independent experiments with triplicate samples for
each condition.
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5.4 Discussion
We have used a Vero-d2EGFP assay to detect Stx activity and inhibitors of
Stx activity. Stx inhibits protein synthesis. Vero-d2EGFP cells that have been
exposed to Stx will halt synthesis of any new d2EGFP. Since the construct has a
short half-life, d2EGFP will be rapidly removed from the Stx-treated cell by
proteasomal degradation. Thus, cells that are exposed to Stx will eventually lose
all fluorescence from the d2EGFP protein. This novel method of detection of Stx
activity is simple and quantitative and has numerous advantages over the current
methods of detection. The assay, which could be used for a high-throughput
screen can be reduced to three steps: 1) seed cells to a 96-well plate, 2) add
toxin and 3) read the fluorescence. The Vero-d2EGFP assay was capable of
detecting picogram concentrations of Stx either as a purified toxin or in cultured
supernatants103. The Vero-d2EGFP can also be used to identify inhibitors of
toxin activity. Plant compounds have been previously shown to inhibit cholera
intoxication and also the release of Stx from EcO157119-121. The data suggest
that plant compounds are potential targets for therapeutic development. Two
preliminary screens for toxin inhibitors using plant compounds revealed two
potential hits. Grape seed and grape pomace extracts both reduced the loss of
fluorescence signal in cells exposed to Stx. This data was confirmed by an
alternative method monitoring total levels of protein synthesis.
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5.5 Future Directions
The identification of two positive hits from our initial screen confirms that the
Vero-d2EGFP assays can be used to identify inhibitors of Stx activity. The active
component(s) in the grape seed and grape pomace extracts that are responsible
for the antitoxin properties has yet to be identified. Further investigation will need
to be carried out using the individual components that make up the extracts. It is
possible that one component alone is responsible. It is also possible that
multiple components are working in a synergy to confer resistance.
Initially the screen was established to identify potential compounds that
would confer resistance to ETA and ricin simultaneously. Since both of these
toxins reach the ER by different trafficking pathways it was likely that any
compounds that conferred resistance to both toxins, would target the ERAD
pathways. Protein synthesis assays were conducted to determine the cell line
that was most susceptible to both ETA and ricin (table 5-1). Vero-d2EGFP assay
data indicate that grape seed and grape pomace inhibit the activity of ETA and
ricin. The exact mechanism for the inhibition is not known. It is possible that the
compounds are: neutralizing the toxin prior to entry into the cell, inhibiting binding
to the cell, altering trafficking within the cell or disrupting interactions with their
host cytosolic targets. Future studies will determine the molecular basis for
cellular protection against Stx, ETA, ricin and possibly other AB protein toxins.
Full statistical validation of the Vero-d2EGFP assay using the established
NIH Chemical Genomics Center assay validation guidelines122 must be
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conducted prior to high-throughput screening. Full validation consists of a 3 day
Plate Uniformity and Signal Variability Study as well as a Replicate-Experiment
study. Each of the three days in the Plate Uniformity and Signal Variability Study
requires three, 96-well plates measuring the maximal signal (max), the
background signal (min) and a point in between the max and min signals (mid),
using the layout provided by the NIH Chemical Genomics Center assay
validation guidelines. The mean (AVG), standard deviation (SD), and confidence
value of the mean (CV) should be computed for each signal (max, mid, min) on
each plate. The CV should be calculated taking into account the number of
replicates per condition.

(

CV = SD

n

) AVG

The acceptance criterion are that the CV’s of each signal be less than or equal to
20%. For each of the mid signal wells, a percent activity (or inhibition) should be
calculated relative to the means of the max and min signals of the same plate
%Activity =

wellmid − AVG min
×100
AVG max − AVG min

%Inhibition = 100 − %Activity

The mean and SD for the mid-signal percent activity (or inhibition) should be
calculated for each plate and should be less than or equal to 20 on all plates.
The assay performance can be calculated using either the Signal Window (SW)
or the Z’ factor (Z’) for each plate where n is the number of replicates for each
condition.
SW =

(AVG

max

− 3SD max

)(

n − AVG min + 3SD min
SD max
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n

n

)

Z' =

(AVG

max

− 3SD max

)(

n − AVG min + 3SD min

n

)

AVG max − AVG min

The acceptable criterion are SW ≥ 2 or Z’ ≥ 0.4 on all plates. Plotting the max,
mid and min signals versus the well number will determine if any drift or edge
effects are present. Replicate-Experiment studies are used to evaluate the
variability within the assay and should be performed as described by the NIH
Chemical Genomics Center assay validation guidelines with the assistance of a
statistician.
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Cell Line
Vero
HEP2
BHK
Hek293
HeLa

ETA EC50
3 ng/ml
100 ng/ml
3 ng/ml
100 ng/ml
10 ng/ml

Ricin EC50
0.25 ng/ml
1 ng/ml
>10 ng/ml*
3 ng/ml
8 ng/ml

Table 5-1 EC50 for ETA and Ricin
Protein synthesis levels were measured in various cell types that were incubated
overnight at 37°C with various concentrations of ETA or ricin. EC50 values for
each cell type are shown. * no inhibition of protein synthesis was detected at this
concentration.
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CHAPTER 6 GENERAL DISCUSSION
Many AB protein toxins are category B agents on the CDC list of bioterrorism agents. Many AB toxins are also commonly associated with food- or
waterborne disease. While antibiotics are available to treat some of the
infections, prevention of toxin action is an ideal target for alternate therapeutic
approaches. AB toxins all face the same problem. They all bind to the cell
surface and must cross a membrane barrier to reach their cytosolic target. Some
of the AB toxins utilize ERAD to translocate into the cytosol. The use of one
pathway by so many toxins makes ERAD an ideal candidate for a therapeutic
target. Understanding the cell biology of intoxication will help to develop novel
treatments for intoxication.
Our study began with the investigation of a normal ERAD protein, HEDJ.
Within the ER, HEDJ serves to recognize exposed hydrophobic residues that are
the hallmark of a misfolded protein96. Upon binding, HEDJ recruits another
ERAD protein, BiP96 that allows the substrate to reach a folded conformation.
HEDJ has been shown to interact with the AB toxin, Stx97. Here we
demonstrated that HEDJ is involved in CT intoxication. Our results reveal that
HEDJ is one of the few eukaryotic proteins that interact directly with multiple
toxins. The disruption of HEDJ function results in decreased toxicity, confirming
our initial hypothesis that disruption of ERAD would prevent intoxication. Based
on the HEDJ studies, we demonstrated that the thermal unfolding of CTA1 plays
a role in CTA1-HEDJ interactions. These data show that HEDJ masks the
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surface exposed hydrophobic residues of unfolded CTA1. It is believed that the
masking of these residues sequesters unfolded CTA1 to prevent aggregation
prior to interaction with BiP. These data suggest that CTA1 interacts with HEDJ
in a manner consistent with a misfolded protein in the ER. These data also
provide us with a target for a potential therapeutic, as the disruption of HEDJ
function disrupts CT intoxication.
The current model for CTA1 transloctation asserts that, upon entry to the
ER, the ERAD protein PDI actively unfolds CTA1. This suggests a novel function
for PDI. An alternate theory is that CTA1 is thermally unstable and that arrival in
the ER triggers a series of events that results in CTA1 dissociating from the rest
of the holotoxin in a partially unfolded conformation. This partially unfolded
conformation triggers the binding of HEDJ and the subsequent export from the
ER, where CTA1 can act upon its cytosolic target. The Teter lab has previoulsly
reported a temperature-dependent loss of CTA1 tertiary structure101. Here we
showed that stabilization of the CTA1 tertiary structure with a chemical
chaperone such as glycerol stabilizes the structure of CTA1 and prevents both
the translocation event and intoxication123. While glycerol itself would be toxic
and could not be administered to patients, our results indicate that the
stabilization of the tertiary structure of CTA1 is another target for therapeutics.
Through the first two aims in this study we identified two potential targets
for therapeutics. Through the development and execution of a high-throughput
screen we hoped to identify compounds that could confer resistance to multiple
AB toxins. We found that two grape extracts were capable of inhibiting the toxic
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effects of ricin and ETA as well as Stx. The active component in the grape seed
and grape pomace extracts has yet to be identified. The molecular basis for the
inhibition of toxicity also remains unknown. Our screen, however, shows that we
can identify inhibitors of toxic activity, providing proof-of-principle for the
execution of the screen with a larger library of compounds.
Based on the collective results presented here we have suggested an
alternative to the current model of CTA1 translocation. It is currently believed
that CTA1 is a thermally stable protein that enters the ER and is actively
unfolded. The current model suggests that ERAD protein PDI acts in a novel
fashion to unfold CTA152. Once CTA1 attains an unfolded conformation, it is
capable of exiting the ER and acting upon its cytosolic target. Our model
suggests that CTA1 is thermally unstable. We have shown that CTA1 attains
unfolded conformation at 37°C in the absence of PDI. The unfolding of CTA1
results in surface exposed hydrophobic residues that are recognized by the
ERAD protein HEDJ. Interaction with HEDJ ultimately results in translocation to
the cytosol. We have shown that stabilization of CTA1 structure or disruption of
ERAD blocks the translocation event and intoxication.
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